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ABSTRACT
Background: Left ventricular assist devices (LVAD) are operated at constant
speeds (rpm), consequently, pump flow is passively determined by the pressure
difference between the LV and aorta. Since the diastolic pressure gradient (~70 mmHg) is
much larger than the systolic gradient (~10 mmHg), the majority of pump flow occurs
during systole. This limitation results in sub-optimal LV volume unloading, LV washing,
and diminished vascular pulsatility that may be associated with increased risk for
clinically-significant adverse events, including stroke, bleeding, arteriovenous
malformations, and aortic insufficiency. To address these clinical adverse events, an
intelligent control strategy using pump speed modulation was developed to provide
dynamic LV unloading during the cardiac cycle to produce near-physiologic pulsatile
flow delivery similar to that of the native heart.
Materials and Methods: The objective of this study was to integrate a novel
algorithm to dynamically control Medtronic HVAD pump speed and demonstrate proofof-concept by characterizing hemodynamic performance in a mock flow loop primed
with a blood analog solution (glycerol-saline, 3 cP) and tuned to simulate class IV heart
failure (HF). The intelligent LVAD control was operated a varying pump speeds (Dspeed
= 0, 1000, 1500, 2000, 2500 rpm) and systolic durations (30%, 35%, and 40%); systolic
duration correlates to the time spent at either the high or low pump speed setting. The
intelligent LVAD control strategy modulates pump speed within a cardiac cycle triggered
from an R-wave of an EKG waveform set to 80 BPM. This pump speed modulation
control strategy allows for pulsatile operation of a continuous flow LVAD within a single
cardiac cycle. Hemodynamic waveforms (LV pressure-volume, aortic pressure-flow, and
pump flow) and intrinsic pump parameters (speed and current) were recorded and
v

analyzed for each test condition. We hypothesize that pump speed modulation may be
configured for optimal volume unloading (rest), vascular pulsatility (reloading), and/or
washing.
Results and Discussion: The intelligent LVAD control system successfully
demonstrated the ability to rapidly increase and decrease HVAD pump speed within a
single cardiac cycle to provide asynchronous, synchronous co-pulsation, and synchronous
counter-pulsation profiles for all systolic durations (30, 35, 40%) and Drpm tested
(D1000, D1500, D2000, D2500). Asynchronous support was achieved when pump speed
increase (or decrease) was independent of the cardiac cycle, co-pulsation support was
achieved when increase in pump speed was timed with beginning of systole
corresponding with ventricular contraction (systole), and counter-pulsation support was
when increase in pump speed was timed with the end of systole corresponding with
ventricular filling (diastole). Ideally, the intelligent control would increase (or decrease)
the HVAD pump speed instantaneously upon R-wave detection; however, two distinct
time delays were observed: (1) a time delay from detection of the R-wave trigger and
increase (or decrease) of pump speed for systolic durations of 35% and 40% (being 45 ±
3.0 ms and 82 ± 3.0 ms respectively and (2) a delay in LVAD flow when pump speed
was increased which is hypothesized to be from the blood analog solution’s fluid inertia.
Left ventricular stroke volume decreased for all LVAD pump speed modulation operating
conditions compared to baseline (HF with LVAD off) indicating that the intelligent
control strategy was able to reduce LV volume with increasing HVAD support. The
highest flow was achieved with the HVAD operated at a fixed speed of 4000 rpm;
however, co-pulsation pump speed modulation at the largest pump speed differential (low
= 1500, high = 4000, Drpm = 2500, and systolic duration 30%) resulted in a mean pump
vi

speed 3,300 ± 1,200 rpm. By comparison, the forward flow at fixed pump speed of 4,000
rpm was 4.8 L/min compared to a mean co-pulsation rpm was 4.5 L/min. Additionally,
all operating settings for the intelligent control during pulsatile function produced an
average forward flow through the aortic valve, while in contrast at higher fixed speeds
(3,500 and 4,000 rpm) the mean aortic flow was negative. Pulse pressure (DP) decreased
with increasing mean pump speed (rpm) for all operating modes (fixed, asynchronous,
co-pulsation, counter-pulsation). When operating at the same mean pump speed (rpm) copulsation has increased hemodynamic benefit for pulsatility when compared to counterpulsation and fixed speed at the same mean pump (rpm).
Conclusion: The results of this study show the ability of the intelligent HVAD
control strategy to increase and decrease pump speed within a single cardiac cycle. This
study showed that asynchronous modulation with phases of co-pulsation can generate
near physiologic pulse pressure and vascular pulsatility when compared to counterpulsation support, while counter-pulsation can generate greater ventricular volume
unloading and diastolic augmentation when compared to co-pulsation. Furthermore, the
clinical impact of this study is that through speed modulation adverse events of
continuous flow LVADs may be reduced such as incidences of bleeding associated with
decreased pulsatility and a decrease in the risk of thrombus formation from poor washing
around the aortic valve.
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I.

BACKGROUND

A. Overview
Heart failure (HF) can be defined as a chronic condition in which the heart is no
longer able to adequately pump blood to the body to satisfy the bodies oxygen and
nutrient demands. HF accounts for approximately 330,000 adult deaths in the United
States annually (Benjamin et al., 2018). HF classification can be divided into four
classes based on physical limitations as well as cardiovascular disease severity, with
lower level classes (I-II) constituting early stage HF and higher-level classes (III-IV)
constituting end stage HF. The classification of HF is used to determine treatment
plans for patients depending on the progression and severity of their disease. Early
stage HF is often treated with optimal medical management (OMM) that target HF
symptoms and improve patient quality of life. End stage HF may also continue to be
treated with OMM, heart transplant, and/or mechanical circulatory support, including
an implantable left ventricular assist device (LVAD).
LVADs are designed to augment the diseased heart in pumping blood to the body
by pulsatile or continuous flow delivery, such as the pulsatile Thoratec HeartMate
XVE (Abbott, Chicago, IL) LVAD and a continuous flow HeartWare HVAD
(Medtronic, Minneapolis, MN) as shown in Figure 1. LVADs are surgicallyimplanted through open chest thoracotomy, with the device placed in the chest. The
1

inflow cannula is implanted into the apex of the left ventricle (LV) and an outflow
graft attached to the aorta (Ao) of the HF patient to deliver forward flow from the LV
to the Ao. Electrical power and communication to the LVAD is provided through a
driveline from the pump to an external controller that is tunneled subcutaneously and
exits through the HF patient’s skin.

2

3

3

1
2

1

Figure 1. Thoratec HeartMate XVE (pulsatile flow) (left) and Medtronic HVAD
(continuous flow) left ventricular assist devices (LVADs). Both LVADs have a
driveline (1) that exits the skin to communicate with the device’s controller, an
inflow cannula (2) that is inserted into the apex of the left ventricle (LV), and an
outflow cannula (3) that is sewn to the aorta. The HeartMate XVE propels blood
by moving a driver bearing against a pusher plate to eject and fill the device. Blood
flow is equal to the amount of volume that the device has and is a fluid
displacement pulsatile LVAD. The HeartWare HVAD produces forward blood
flow by the rotation of an impeller creating a continuous flow of blood through the
device and out of the outflow graft to the aorta to supply blood to the remainder of
the body.

2

LVADs have become a valuable tool in the treatment of advanced HF by helping
bridge the gap between the large, growing number of advanced HF population and the
limited number of donor hearts available for transplantation each year. LVADs have
become more clinically accepted in recent years due to improved survival rates of
continuous flow LVADs (CF-LVADs) being approximately 80% and 70% after one and
two years of support respectively (Kirklin et al., 2017) comparable to heart
transplantation survival rates. Although there are currently approximately, 2,400 LVAD
implants a year in the US (Benjamin et al., 2018), adverse events such as bleeding, pump
thrombosis (which could lead to stroke if the thrombus detached from the pump),
infection, and an increased risk of developing right heart failure are associated with CFLVAD use (Patel et al., 2014). Infection events are more prominent immediately
following LVAD implantation due to the surgical procedure of having an open chest
cavity to implant the device (Patel et al., 2014). Pump thrombosis and bleeding are two
interconnected adverse events associated with anticoagulation regiments that are
administered to LVAD patients. Anticoagulants are administered to patients to reduce the
risk of thrombus formation due to the patient’s blood being exposed to a foreign body
(the LVAD); nevertheless, this therapy may increase the risk of bleeding events by
lowering the responsiveness of the body’s natural clotting mechanisms. In addition to
anticoagulation medications, rotary blood pumps produce high shear stress on blood and
platelets, which has been theorized to create molecular changes in clotting factors,
including von Willebrand factor (Patel et al., 2014), that may increase the risk of a
clinically-significant bleeding event. The adverse events associated with CF-LVADs may
also be due, in part, to non-physiologic volume unloading and reduction in pulsatility
(Soucy et al., 2013) as a result of operating at fixed pump speeds. Due to the increased
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occurrence of these clinical adverse events with rotary blood pumps, which were not as
commonly seen in patients with pulsatile flow devices, development of control strategies
that enable CF-LVADs to behave more physiologically (dynamic LV volume unloading
and pulsatility) has been proposed. Specifically, modulating rotary pump speed (rpm) of
CF-LVADs to create a pulse has been proposed as a potential solution to help mitigate
the incidence of adverse events. Modulating CF-LVAD pump speed (rpm) is achieved
by cyclically increasing and decreasing the current that is supplied to the device. The
current is delivered to the pump from the LVAD controller through the driveline and is
used to set the operating pump speed (rpm) of the device. Thus, pump speed modulation
may be achieved by altering the current supplied to the device within a specified time
period as opposed to operating in a continuous flow mode at a fixed pump speed.
This thesis research tests the feasibility of pump speed modulation within a single
cardiac cycle using the Medtronic HVAD configured with an intelligent LVAD control
strategy in a benchtop mock circulatory loop testing platform. The intelligent control
strategy triggers pump speed modulation with detection of an R-wave landmark from an
electrocardiogram (EKG) to rapidly increase and decrease pump speed to produce
dynamic LV volume unloading and pulsatile flow using a CF-LVAD rotary pump.

B. Heart Failure
1. Epidemiology
HF has been declared a global pandemic affecting approximately 26 million people
worldwide and nearly 6.2 million people in the United States (US, Savarese et al., 2017;
Benjamin et al., 2019). HF prevalence in the US is expected to increase to over 8 million
people by 2030 with an average of approximately 550,000 new cases diagnosed each year
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across all age groups, as shown in Figure 2 (Benjamin et al., 2017; Heidenreich et al.,
2013).
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Figure 2: Projected heart failure population in the United States, data in this graph has been
modified displayed graphically from Heidenreich et al., 2013.

Currently, HF is the leading cause of adult mortality in the US with nearly 330,000
deaths reported annually (Benjamin et al., 2018). The total medical cost of care for HF
patients is estimated at $30.7 billion dollars and is expected to increase 127% to $69.7
billion by 2030 (Heidenreich et al., 2013), which includes medical, surgical, and rehospitalization expenses associated with HF therapy.

2. Classification
HF may be defined as a chronic condition with the heart losing the ability to
adequately deliver enough blood to satisfy the oxygen and nutrient demands of the body.
Left ventricular (LV) HF failure may be categorized as systolic and/or diastolic
dysfunction. Diastolic dysfunction is characterized by abnormalities in the filling of the
5

LV and often results in preserved ejection fraction of patients which may result from
slowed LV relaxation and increased stiffness of the LV (Abebe et al., 2016; Paulus et al.,
2007). Systolic HF may be characterized by the diminished ability of the heart to eject
blood within each cardiac cycle resulting in a reduced LV ejection fraction (Chatterjee et
al., 2008). HF resulting from myocardial damage is a subset known as ischemic HF that
is generally caused by coronary artery disease due to the decreased blood flow through
the coronaries to the myocardium. Non-ischemic HF (NI-HF) is a subset of HF that does
not result from coronary artery disease, but rather is characterized by myocardial damage
leading to ventricular dysfunction. NI-HF has been hypothesized to stem from many
potential causes not linked directly to coronary artery disease, which include but are not
limited to infection, genetic factors, and immune system abnormalities (Wu et al., 2007).
The New York Heart Association (NYHA) defines HF by four distinct categories
(Table I) based on patient symptoms (including dyspnea, fatigue, or peripheral edema)
and their inability to perform various exercise tasks (Burgess et al., 2016; Mosterd et al.,
2007). Table I lists the functional capacity and objective assessment for each heart failure
classification based on the NYHA guidelines (Athilingam et al., 2013). Class III-IV are
considered end stage (advanced) HF while classes I-II are considered early stage HF
(Friedrich et al., 2007). Depending on the patient’s HF classification and the progression
of the disease, varying medical treatments such as OMM, heart transplant, and/or
mechanical circulatory support (MCS) may be more suited for specific stages of HF.

6

TABLE I
NEW YORK HEART ASSOCIATION HEART FAILURE CLASSIFICATION

New York Heart Association (NYHA) classification of heart failure. Class I represents
the least severe stage of heart failure with its objective assessment described by the
NYHA and class IV describes the most severe stage of heart failure and its objective
assessment. Classification table was modified and recreated from Athilingam et al.,
2013.
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3. Etiology
Due to HF having several underlying mechanisms of progression there is not one
common cause for all HF patients. HF may be multi-variable leading to varying diseases
of the myocardial tissue also known as a cardiomyopathy. Cardiomyopathies may be
associated with hypertension, viral myocarditis, valvular disease, genetic predisposition,
and coronary artery disease (CAD) (Wexler et al., 2010; Maron et al., 2006). In addition
to these cardiomyopathies, other risk factors for the development and progression of HF
include diabetes mellitus, aging, smoking, obesity and an excess dietary sodium intake
(Frohlich et al., 2014). CAD is considered to be the predominant cause of ischemic HF
and is estimated to be the underlying etiology of nearly 70% of patients (Gheorghiade et
al., 1998). CAD is defined as the narrowing or blocking of the arteries that supply blood
to the heart (coronaries). Reduced blood flow to the heart may result in death of
myocardial tissue that may also lead to worsening LV function. With this subsequent
myocardial tissue injury or death, a variety of compensatory mechanisms may be
activated to try and maintain required cardiac output.

4. Pathophysiology
The basic underlying physiologic mechanisms in the development and progression of
chronic HF are an initial insult (i.e. myocardial infarction) followed by ventricular
remodeling (Delgado et al., 1999). Ventricular remodeling may be described as the
myriad of compensatory mechanisms that subsequently take place temporally and
spatially both in response to the dysfunction and as a consequence of the dysfunction.
(Monreal et al., 2004)). The initial insult may reduce systolic function of the heart by
damaging the surrounding myocardial tissue. This damage can then subsequently
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diminish the ability of the myocardium to contract and produce blood flow to the body
resulting in reduced cardiac output. The heart attempts to compensate for this condition
by increasing heart rate and ventricular remodeling. Ventricular remodeling is initially an
adaptive response to the initial insult in order to maintain pump function (Delgado et al.
1999). However, over time the remodeling cascade progresses both temporally and
spatially resulting in altered size, shape, and function of the ventricle through scarring,
activation of growth factors, and molecular changes of the myocardium (Delgado et al.,
1999; Azevedo et al., 2015).
One compensatory response to low cardiac output is known as the Frank-Starling
mechanism. The Frank-Starling mechanism describes the hearts ability to alter the force
of ventricular contraction in response to venous return. By increasing the venous return of
the heart (preload) the LV myocardium stretches allowing for greater force generation
and contractility due to increased tension in the myocardium of the failing ventricle,
subsequently increasing the stroke volume and cardiac output if the HR remains constant
(Kemp et al., 2012; Sequeira et al., 2015). Additional compensation responses target the
release of renin from the kidneys in an attempt to maintain normal renal and systemic
perfusion by increasing the retention of water and salt; however, if this response is
prolonged this can lead to the development of edema and increases the afterload on the
diseased heart, furthering the progression of the disease (Delgado et al., 1999).
Myocardial damage and worsening LV function leading to decreased contractility of the
ventricle increases left ventricular volume, decreases stroke volume, elevates end
diastolic pressure and volume, produces a rightward shift in the ventricular pressurevolume (PV) relationship, and decreases aortic pressure, and pulse pressure, as illustrated
in Figure 3.

9

Figure 3. Illustration of pressure volume (PV) loops to visualize differences between an expected
healthy PV loop and expected heart failure (HF) PV loop (top). HF failure PV loop has distinct
right-ward shift and increased end diastolic pressure as a result of diminished contractile strength
and dilation of the left ventricle. Additionally, the HF PV loop has a smaller difference between
systolic and diastolic left ventricular pressures represented in the truncation of the loop when
compared to the expected PV loop of a healthy adult. Hemodynamic waveforms recorded in a
mock circulatory loop to simulate a class IV HF baseline (bottom). Left ventricular end systolic
and aortic pressures are reduced from expected healthy adult, while end diastolic pressures are
elevated. Stroke volume or the difference between maximum and minimum left ventricular
volume is also expected to be reduced when compared to a healthy adult.
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5. Deviation from Normal Cardiac Physiology
Significant changes in anatomic features and hemodynamic parameters occur in
the transition from a healthy heart to diseased HF heart. Anatomically, the left ventricle
becomes dilated and the myocardial walls thin (Inamdar et al., 2016). In advanced HF
stages, left atrial pressure (mean) and left ventricular pressures (end-diastolic) increase,
aortic and left ventricular pressures (systolic, mean) decrease, cardiac output is reduced,
and heart rate increases, as listed in Table II (Yildiran et al., 2010; Melenovsky et al.,
2015). As shown earlier in Figure 2, an adult with a healthy heart compared to stages of
advanced HF will have a larger stroke volume, lower end diastolic pressure (reduced
preload), greater ventricular contractility, and lower end systolic and end diastolic
volumes.
TABLE II
HEMODYNAMIC PROGRESSION OF HEART FAILURE FROM NORMAL FUNCTION
Comparison of Hemodynamic Paremters
Parameter

Healthy

Class I

Class II

Class III

Class IV

Systolic Blood Pressure (mmHg)

1,2

<120

127 ± 15

123 ± 23

107 ± 15

98 ± 12

Mean Arterial Pressure (mmHg)

1,2

70-105

98 ± 10

93 ± 15

82 ± 10

77 ± 9

1,2

<80

83 ± 9

78 ± 11

70 ± 9

66 ± 8

~30-40

45 ± 10

46 ± 15

37 ± 11

31 ± 9

55-75

35 ± 5

35 ± 5

28 ± 5

25 ± 5

4-12

20 ± 8

20 ± 8

20 ± 8

20 ± 8

65-80

81 ± 7

82 ± 14

89 ± 17

92 ± 15

Diastolic Blood Pressure (mmHg)
Aortic Pulse Pressure (mmHg)
Ejection Fraction (%)

1,2

Left Atrial Pressure (mmHg)
Heart Rate (BPM)

1,2

1,2

3,4

Table II displays the progression from a healthy adult to advanced heart failure. With progression of
heart failure, the aortic blood pressure decreases during both systole and diastole, in addition to a
decrease in the aortic pulse pressure, due to the inability of the diseased heart to generate as much force
when compared to a healthy adult. Also, ejection fraction diminishes with progression of heart failure
due to decreased ventricular contractility. Left atrial pressure (preload) is elevated when compared to
healthy adults due to volume overload that takes place in heart failure patients. Finally, the heart rate is
increased as a mechanism to attempt to increase the cardiac output with the progression of heart failure.
Data is represented as mean +/- standard deviation and was created using data modified from Yildiran
et al., 2010 ; Cleveland Clinic, Ejection Fraction , Edwards. Normal Hemodynamic Parameters , 2014,
Melenovsky et al., 2015 .
1

2

3

4
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C. Treatments
1. Medical Management
The main objective of optimal medical management (OMM) of HF patients is to
relieve the symptoms associated with the disease and help to improve their quality of life,
functional capacity, and reduce the risk of hospitalization and mortality (Berliner et al.,
2017). Some pharmacological therapies for HF patients include the use of angiotensin
converting enzyme (ACE) inhibitors (ACEIs), mineralocorticoid receptor antagonists
(MRAs), and beta blockers (Berliner et al., 2017; Shah et al., 2017). Beta blockers
(adrenergic receptor antagonists) are used to reduce the workload on the heart through the
reduction in sympathetic stimulation on the heart and vasculature (Shah et al., 2017).
ACEIs act by helping to reduce the workload on the heart by vasodilation decreasing
peripheral resistance and to reduce the afterload that the heart has to pump against
(Berliner et al., 2017; Shah et al., 2017). Goals of OMM for treating HF patients include
alleviating symptoms which may impact quality of life and reducing morbidity and
mortality of the disease.

2. Heart Transplant
The gold standard in care for patients diagnosed with advanced HF is a heart
transplant. The first successful heart transplant was performed over 50 years ago in 1967.
Since 1990, approximately 2,000-2,500 transplants are performed annually in the US
(Koomalsingh et al., 2018). Survival rates after heart transplant have steadily improved
by approximately 10% for 1-year and 5-year survival rates when compared to the 1980s
(Wilhelm et al., 2015), with recent data showing 1-year, 4-year, and 10-year survival
rates at 90%, 80%, and 65%, respectively (Lund et al., 2016).

12

There are many limitations and clinical challenges associated with heart
transplantation. Despite a slight increase in the number of transplants over past several
years (approximately 500 additional transplants) there continues to be an insufficient
supply of donor organs available to meet the current and projected demand estimated to
be up to 550,000 HF patients annually (Benjamin et al., 2018). Additionally,
comorbidities, such as irreversible pulmonary hypertension, systemic infection, inability
to comply with the complex medical regimen, and irreversible dysfunction of the liver or
kidneys are known contraindications (Jonge et al., 2008; Taylor et al., 2006). Donor
availability, organ rejection, and immunosuppression management are among the most
common limitations associated with heart transplant therapy (Sing et al., 2015).

3. Mechanical Circulatory Support
Mechanical circulatory support (MCS) devices have been used to support NYHA
Class III-IV patients (Katz et al., 2015). These devices have been approved for use in
advanced HF patients as bridge to heart transplantation (BTT), bridge to recovery (BTR),
bridge to heart transplant candidacy (BTC), and/or destination therapy (DT) (Puehler et
al., 2014). Short-term MCS devices are currently being used as a bridge to decision in
patients with refractory cardiogenic shock defined as the condition resulting in tissue
hypoxia from a reduced cardiac output (Reyentovich et al., 2016). These patients may
then be transitioned to long-term MCS or BTR. Commonly used short-term devices
include intra-aortic balloon pumps (IABPs), Impella 2.5 & 5.0, TandemHeart, and
extracorporeal membrane oxygenation (ECMO) (den Uil et al., 2017).
IABPs are devices that provide diastolic augmentation using the principle of
counter-pulsation defined by augmenting flow during diastole and reducing pressure and
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afterload during systole of the native heart. An IABP is placed in the descending aorta.
During diastole the balloon rapidly inflates causing blood flow to be displaced equal to
the volume of the balloon back toward the ascending aorta to perfuse the coronary
arteries and to the descending aorta to improve end-organ perfusion. During systole the
balloon rapidly deflates creating a vacuum that decreases the aortic pressure, improves
left ventricular unloading, and increases cardiac output (Gilotra et al., 2014).
The Impella system (ABIOMED, Danvers, MA) consists of an axial rotary pump
embedded in a catheter that is placed across the aortic valve and can deliver 2.5 to 5.0
L/min blood flow from the LV to the aorta. The Impella 2.5 is implanted by a cardiac
catheterization procedure, and the Impella 5.0 is implanted via a femoral cutdown. These
devices have a pigtail-tipped catheter that sits inside the left ventricle and pumps blood
out the ascending aorta. These devices operate asynchronously (independent of the
cardiac cycle) and produce continuous flow to the ascending aorta (Sarkar et al., 2010).
The Impella has been shown to be effective in patients with cardiogenic shock and
percutaneous coronary intervention (PCI) by increasing cardiac output, reduces
ventricular volume, and improving myocardial supply-demand ratio (Kawashima et al.,
2011; Mukku et al., 2012).
TandemHeart (CardiacAssist Inc., Pittsburgh, PA) is a percutaneous ventricular
assist device (pVAD) that is implanted in a left atrial to femoral artery bypass system.
The pVAD consists of a continuous flow centrifugal blood pump and an arterial
perfusion catheter. The pVAD draws oxygenated blood from the left atrium that is
pumped to the systemic circulation via a femoral artery catheter to bypass the left
ventricle of the heart (Gilotra et al., 2014). The hemodynamic benefits of pVAD use
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include reduced LV stroke volume and LV preload while increasing cardiac output when
compared to an IABP or Impella (Gilotra et al., 2014; Ergle et al., 2016).
Extracorporeal Membrane Oxygenator (ECMO) therapy consists of a centrifugal
pump and an external oxygenating system for carbon dioxide and oxygen gas exchange.
There are two forms of ECMO based on cannulation site: (1) femoral artery and vein
(venoarterial, VA) or (2) internal jugular vein and femoral vein (venovenous, VV). In VA
ECMO the patient is provided with both respiratory and hemodynamic support therapy,
whereas in VV ECMO the patients have stable hemodynamics, subsequently only
respiratory support is required (Makdisi et al., 2015). Advantages of ECMO include the
ability to oxygenate blood in hypoxemic states and unload both ventricles
simultaneously. Overall the goal of short-term MCS devices is to reduce the afterload and
preload on the failing heart while increasing cardiac output to provide better perfusion to
the rest of the body (Gilotra et al., 2014).
Ventricular assist devices (VADs) and total artificial hearts (TAHs) are MCS
devices designed for long-term support. TAHs are currently approved for use in endstage biventricular HF as a BT. Currently, the only FDA approved TAH in the United
States is the CardioWest TAH (SynCardia Systems, Inc, Tucson, AZ). The CardioWest
consists of two polyurethane ventricles with stroke volumes of 70 mL. To implant the
CardioWest TAH, (1) the ventricles are excised, (2) quick connects of the TAH are
sutured to the valve annulus, mitral valve annulus for the left side of the heart, and the
tricuspid valve annulus for the right side of the heart, and (3) the aortic and pulmonary
artery grafts are then connected (Cook et al., 2015).
LVADs may be classified as pulsatile flow VADs (PF-VADs) and CF-LVADs,
which are both able to be implanted into the left or right ventricle by surgically grafting
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the inflow cannula into the apex of the ventricle and the outflow graft to either the aorta
(LVAD) or pulmonary artery (right ventricular assist device). VADs augment the heart
by volume unloading the ventricle (reduce workload) and restoring cardiac output to
adequately perfuse end-organs. These devices may be placed completely inside the chest,
extracorporeally, or percutaneously. With devices placed percutaneously inflow and
outflow cannulas are tunneled into the chest in instances of larger devices not having
adequate room to be implanted inside the chest. The first-generation devices were PFVADs that were large in size and weight, had many moving parts, and limited durability
(Soucy et al., 2013). PF-VADs were actuated using a pneumatic driver to rapidly inflate
and deflate an artificial membrane, such as the Thoratec PVAD (Pleasanton CA), or
electro-mechanically using a pusher-plate mechanism, such as the Thoratec XVE
(Pleasanton CA) to produce near-physiologic pulsatility and dynamic volume unloading.
These devices have been replaced by second generation CF-VADs, including the
HeartMate II (Abbott, Chicago, IL) and HeartWare HVAD (Medtronic, Framingham,
MA), that continuously unload ventricular volume and deliver blood flow through the
aorta by the constant fixed speed rotation of high-speed impeller (4,000-10,000 rpm)
using axial or centrifugal design configurations. CF-VADs are smaller in size and weight,
require fewer moving parts and no valve, and have demonstrated significantly improved
durability (Soucy et al., 2013). Despite the improvement in MCS device technology,
concern with clinically-significant adverse events, including bleeding, pump thrombus,
and stroke, may be associated (and have been hypothesized) with the non-physiologic
conditions (small fixed volumes, diminished pulsatility) of rotary blood pumps operated
at fixed impeller speeds.
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D. Challenges of VAD Support
As MCS devices have gained widespread clinical use, common clinical
complications and significant adverse events associated with CF-LVADs have been
reported, including bleeding, pump thrombosis (stroke), infection, and the risk of
developing right heart failure (Patel et al., 2014). Bleeding has been reported in up to
20% of HF patients supported by LVADs (Eckman et al., 2012). Acquired von
Willebrand syndrome has been hypothesized as a potential cause of the reported high
incidence of bleeding due to high shear stress on the blood generated by rotary blood
pumps (Eckman et al., 2012; Nascimbene et al., 2016). Despite use of anticoagulation
during chronic CF-LVAD support, thrombosis is another clinically-significant adverse
event due to the risk of stroke (Eckman et al., 2012). LVAD infections are one of the
most common adverse events with a reported incidence rate ranging from 14-28% (Rose
et al., 2001), and which predominantly occur in the driveline for up to 19% of reported
infections (Goldstein et al., 2012; Hernandez et al., 2017). Depending on the severity of
the infection, clinicians may prescribe two potential treat options: (1) broad-spectrum oral
antibiotics (Toda et al., 2015; Maniar et al., 2011) or (2) surgical intervention by either
driveline debridement or device replacement (Hernandez et al., 2017).
Right ventricular (RV) failure has also been reported following LVAD implantation
with a reported incidence of 9-40% (Fida et al., 2015), which is considered a major risk
factor in the morbidity and mortality of HF patients supported by CF-LVAD (Argiriou et
al., 2014). RV failure may occur when the output of the right ventricle cannot achieve
balance (or keep up with the left ventricle) resulting in high RV preload. There may also
be a leftward shift of the intraventricular septum due to LVAD unloading, especially at
higher pump speeds, that may also contribute to impaired RV contractility (Argiriou et
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al., 2014). Treatment options for patients with RV failure include (1) OMM and/or (2)
surgical intervention. OMM is aimed at keeping the central venous pressure less than 15
mmHg to maintain lower RV workload using inotropes and vasodilators; additionally, the
LVAD may be set at a pump speed that provides sufficient cardiac output without
producing a septal shift toward the LV to help prevent detrimental RV anatomical
changes (Fida et al., 2015; Slaughter et al., 2010). Surgical intervention consists of
implanting a right ventricular assist device (RVAD) to support the failing right ventricle.
Approximately 6-10% of patients with an LVAD will also receive an RVAD, resulting in
bi-ventricular support (Bi-VAD) (Boulate et al., 2014).

E. Pump Speed Modulation
Due to the adverse events associated with continuous flow LVADs, pump speed
modulation has been proposed to produce physiologic ventricular volume unloading and
pulsatility. LVAD pump speed modulation is the concept of varying (increasing and
decreasing magnitude over a defined time period or frequency) pump speed (rpm) rather
than operating at a constant or fixed pump speed. Pump speed modulation may produce
better (more physiologic) hemodynamics compared to continuous mode operation. Pump
speed manipulation may also enable other operation modalities, such as timing of pump
speed manipulation within the cardiac cycle (frequency), pump speed range with defined
high and low settings (magnitude), time spent at each operating rpm (period), and
feedback control using external trigger signal(s) to define pump speed modulation
algorithms.
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1. Pump Speed Modulation: Hemodynamics
Hemodynamic responses with pump speed modulation may vary as a function of
LVAD operating modality, as previously shown in a mock circulatory loop (MCL)
model. The hemodynamics for a simulated class IV HF (no LVAD), continuous flow
using the HVAD (4000 rpm), and pulsatile flow using the HVAD (mean pump speed
3,300 rpm) produced varying hemodynamic responses during this experiment based on
the operating modality of the LVAD (Figure 4). Continuous flow produces decreased
aortic pulse pressure, decreased LV stroke volume, and pulsatility when compared to
pulsatile LVAD operation and class IV HF patients with no LVAD (Soucy et al., 2013).
As shown in Table III, there are several benefits and limitations associated with LVAD
pump speed modulation, including the benefits of decreasing LV workload and
increasing pulse pressure when compared to fixed speed, but at the cost of increased
power requirements and the risk for hemolysis with the rapid change in pump speed
(Soucy et al., 2015).
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Figure 4. Comparison of hemodynamic waveforms for class IV heart failure
(HF) baseline recordings taken in mock circulatory loop and then left
ventricular assist device (LVAD) operation in a continuous flow and pulsatile
flow manner. Of note is decreased pulse pressure in both operating settings of
LVAD but pulsatile operation creates pulse pressure (red-hue area) that is
closer to baseline. Left ventricular volume: LVV, Left ventricular pressure:
LVP, aortic pressure AoP, current supplied to LVAD: current (controls pump
speed).
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TABLE III
BENEFITS & LIMITATIONS OF FIXED SPEED AND PULSATILE
LEFT VENTRICULAR ASSIST DEVICE OPEARTION

Benefits
Fixed Speed

Limitations

LV work = ¯

Aortic Valve Opening = ¯

Power = ¯

DP = ¯

Hemolysis = «

Adverse events

Sensor-less control

DV = ¯

LV work = ¯¯
DV = 
Pulsatile
Operation

DP = 

•

Aortic Valve Opening = 

•

Power = 
Hemolysis = 

Washing = 
Myocardial perfusion = 
 = increases; ¯ = decreases; « = clinically insignificant amounts

Table III. Benefits and limitations associated with both fixed (continuous) speed
operation and pulsatile operation of left ventricular assist devices (LVADs). Pulsatile
operation may have the benefits of improved pulsatility, aortic valve opening, and pump
washing when compared to fixed speed operation while having the drawback of
requiring more power to operate LVADs in a pulsatile fashion. Relationships in this
table have been determined from Soucy et al., 2015.

2. Pump Speed Modulation: Triggering
Pump speed modulation of CF-LVADs may be accomplished using time-dependent
variation (increase or decrease) in pump speed and triggering from an external source
such as detection of specific landmarks within aortic pressure or EKG waveforms.
Current examples of how pump speed modulation may be achieved, include time-based
pump speed modulation algorithms used with Thoratec HeartMate 3 (Burlington, MA),
Lavare cycle using the HVAD, and the Jarvik 2000 (Jarvik Heart, New York, NY)
intermittent low speed controller. Each of these clinically approved LVADs use pump
speed modulation to increase (or decrease) pump speed based on a set time interval of
operation. The HeartMate 3 modulates pump speed every two seconds while the Lavare
cycle and Jarvik 2000 modulate pump speed once per minute independent of external
trigger or time during cardiac cycle. An additional way to trigger pump speed modulation
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is to use an external trigger, such as a pressure waveform or EKG. This technique is
employed when using the IABP that is either triggered by the patient’s EKG or aortic
pressure waveform to provide counter-pulsation support. Triggering from an EKG Rwave detection algorithm is the technique employed in this study using a simulated EKG
from a patient simulator. The intelligent control algorithm detects the R-wave on the
EKG corresponding to ventricular contraction to increase (or decrease) pump speed. This
technique is different from current clinically used pump speed modulation algorithms due
to the feedback that the controller has to time the increase in pump speed from an internal
trigger source and the specific time points in the cardiac cycle to provide support in
asynchronous, co-pulsation, and counter-pulsation modes. The R-wave threshold
detection for triggering pump speed modulation with the intelligent control algorithm
used in this study is shown in Figure 5. This threshold is set at a high enough amplitude
for reliable R-wave detection (true positive) to avoid detection of the P or T-waves (false
positive) and low amplitude ensure cardiac beats are not missed (false negative).

R-Wave Detection Threshold

Figure 5. Illustration of electrocardiogram (EKG) cartoon with R-wave detection
algorithm threshold. Ability in intelligent left ventricular assist device (LVAD) control
strategy to increase or decrease threshold to trigger solely from R-wave without
interference from P or T-wave. The R-wave of the QRS complex is targeted for pump
speed modulation triggering because it corresponds to ventricular contraction
(depolarization) and has a distinct peak and separation from the P and T wave. The Pwave corresponds to atrial contraction (depolarization) in the cardiac cycle while the Twave corresponds to ventricular filling (repolarization).
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3. Pump Speed Modulation: Modalities
Pump speed modulation techniques currently in clinical use focus on increasing (or
decreasing) pump speed using an internal timing interval within the LVAD controller
independent of the cardiac cycle. These techniques are employed in the HeartMate 3, in
the Lavare cycle using the HVAD, and via the intermittent low speed of the Jarvik 2000
as seen in Figure 6. The HeartMate 3 is a centrifugal flow device that is implanted inside
the chest and provides an artificial pulse by lowering operating rpm of the pump by 2000
rpm for 0.15 seconds and then subsequently increasing operating rpm by 4000 rpm for
0.20 seconds before returning to the original fixed speed (Castagna et al., 2017). The
Lavare cycle is a control strategy integrated into the HVAD to provide intermittent pump
washing to reduce the risk of pump thrombosis. The Lavare cycle is an algorithm that
decreases operating rpm by 200 for a period of two seconds and then increases the
operating rpm by 400 for one second and then returns to the operating rpm of the initial
fixed speed (Kumar et al., 2019). The Jarvik 2000 is an axial flow device and was the
first LVAD to utilize cyclic speed rotation (one cycle per minute) to minimize the risk of
thrombus formation by promoting periodic aortic valve opening allowing washing of the
aortic valve.
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Figure 6. Graphical representation of pump speed modulation used by the HeartMate 3,
Lavare cycle (HVAD), and Jarvik 2000 intermittent low speed controller. All techniques
modulate pump speed on an internal time interval independent of cardiac cycle. HeartMate
3 modulates pump speed every two second while the Lavare cycle and Jarvik 2000
modulate pump speed once per minute.

By triggering pump speed modulation from external sources, such as the EKG or
aortic pressure waveforms, pump speed modulation can be timed to increase (or
decrease) pump speed at specific points in the cardiac cycle. Pump speed can be triggered
during specific points in the cardiac cycle to produce co-pulsation (ventricular
contraction), counter-pulsation (ventricular filling), and asynchronous (independent of
cardiac cycle) support, as shown in Figure 6. Pump speed modulation may be timed
using the R-wave EKG trigger (dotted line) for co-pulsation and counter-pulsation to give
support during specific points during the cardiac cycle, while asynchronous pump speed
modulation is increasing (or decreasing) pump speed independent of the cardiac cycle, as
shown in Figure 7.
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Figure 7. Pump speed modulation
based on timing increase (or
decrease) in pump speed with
consideration to the cardiac cycle
recorded in a mock circulatory
loop simulating class IV heart
failure (HF). Asynchronous
modulation increases (or
decreases) pump speed
independently of the cardiac cycle.
Co-pulsation increases (or
decrease) pump speed in response
to R-wave trigger (dotted line) at
the beginning of systole and has
higher pump speed during
ventricular contraction. Counterpulsation increases (or decreases)
pump speed in response to R-wave
trigger (dotted line) at the end of
systole and has higher pump speed
during ventricular filling. EKG:
electrocardiogram, LVP: left
ventricular pressure, AoP: distal
aortic pressure, LVAD flow: left
ventricular assist device (LVAD)
flow, Current: current supplied to
LVAD (controls pump speed).
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In addition to timing pump speed modulation with respect to the cardiac cycle,
pump speed modulation can also be achieved independent of timing (asynchronous). As
shown in Figure 8, pump speed modulation can be controlled by increasing the Drpm
around a fixed mean rpm (black). This strategy increases the rpm above and below a
mean rpm that is consistent between each operating setting. Low pump speed may be set
while the higher operating pump speed is increased, thus changing the Drpm between
operating settings (orange). This would also in turn alter the mean pump speed, due to
mean pump speed being a function of both high and low pump speed settings in addition
to the time spent at each of these settings. High and low pump speed settings may also be
set independent of mean pump speed and/or fixed high or low setting (blue).

Figure 8. Pump speed modulation based on varying pump speed (rpm) settings
around a fixed mean rpm (black), set low speed while altering high pump speed
setting (orange), and changing pump speed settings independent of target mean
rpm or fixed high or low pump speed (blue).
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F. Intelligent LVAD Control
In this thesis project, a Medtronic HVAD was operated using a novel pump speed
modulation algorithm to produce varying degrees of phasic ventricular volume unloading
and pulsatile flow during asynchronous, co-pulsation, and counter-pulsation
hemodynamic support in a MCL model. The HVAD was chosen because it is a clinical
grade rotary blood pump and met the design criteria with required slew rate (defined as
rate of change in pump speed per unit time, i.e. 1000 rpm/ms) for rapidly modulating
(increasing, decreasing) pump speed using the supplied controller current. The intelligent
LVAD control strategy is designed to rapidly increase (or decrease) pump speed with
timing triggered to EKG (R-wave threshold detection) and user-defined duration (period).
An EKG simulator was used to produce an EKG to trigger the intelligent controls pump
speed modulation of the HVAD. The R-wave was selected as the trigger due to it
corresponding to ventricular contraction. The percent time spent at high and low speed as
well as the difference between high and low pump speed (rpm) were the operating
controls varied throughout this experiment, as shown in Figure 9.
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Figure 9. Illustration of intelligent left ventricular assist device (LVAD) control
pump speed modulation controls. Pump speed has two controls the first being the
time spent at the lower pump speed represented by 30, 35, and 40%. Also, the
difference between high and low pump speed represented as Drpm. For this study
the low rpm was set and the Drpm indicates the difference between the low
setting and high setting, with the horizontal dotted line indicating the mean rpm
of each setting. Mean rpm increased with increasing Drpm in this study due to the
fact that the low setting was set, and the high pump speed was increasing
thorough out this study.

We hypothesized that (1) co-pulsation would provide the greatest increase in forward
flow and pulse pressure compared to fixed pump speed due to the HVAD operating at
higher speed during ventricular contraction (systole) and pumping at the lowest pressure
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gradient, while (2) counter-pulsation would provide the greatest decrease in ventricular
volume and workload compared to fixed pump speed due to the HVAD operating at the
highest pump speed during ventricular filing (diastole). We also hypothesized that the
greater the variation in high and low pump speed (Drpm) and the longer the systolic (or
diastolic) duration the greater the hemodynamic benefit that may be achieved. These
hypotheses were tested in a single-sided, mock flow loop model constructed to simulate
hemodynamic values equivalent to clinical NYHA Class IV HF.
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II.

A.

METHODS

Study Overview
The objective of this study was to test the feasibility a novel intelligent control

algorithm designed to rapidly increase and decrease pump speed of a LVAD (Medtronic
HVAD, Minneapolis MN) within each cardiac cycle using a mock circulatory loop
(MCL) model. The MCL was configured and tuned to simulate the systemic
hemodynamics equivalent to NYHA class IV HF state in an adult. The MCL was primed
with a blood analog solution (glycerol-saline) with a viscosity of 3 centipoise (cP)
representing a hematocrit of 38% (Cheng et al., 2008). The goals of this study were 1) to
demonstrate the ability to rapidly increase and decrease HVAD pump speed (rpm) within
each cardiac cycle using R-wave trigger detection and quantifying the slew rate and
trigger response time; 2) to identify HVAD intelligent control operating parameters the
provide the highest degree of dynamic ventricular volume unloading, cardiac output,
and/or vascular pulsatility; and 3) to characterize hemodynamic responses as a function
of (a) fixed speed, synchronous systolic (co-pulsation), and diastolic (counter-pulsation)
timing, (b) systolic or diastolic duration (30%, 35%, 40%), and (c) modulated differential
pump speed (Dspeed = 0, 1000, 1500, 2000, 2500 rpm). We hypothesized that pump
speed modulation will provide better volume unloading (rest), pulsatility (reloading),
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and/or washing (pump, valves, ventricle) than with the LVAD operated at fixed pump
speeds.
B.

Study Design
1.

Intelligent LVAD Control System

The intelligent LVAD control system consists of a controller (hardware) and
programmed algorithms (software). The intelligent HVAD control system uses a HF
patient’s EKG waveform data to identify the R-wave landmark in real-time for every
cardiac cycle using a threshold detection algorithm. The trigger time point (R-wave
detection) is then used to rapidly increase or decrease user-defined pump speeds and the
start and end time-points within the native heart cardiac cycle. The controller software
enables the end-user to define the lower and upper pump speed settings (for a derived
Drpm), time delay from R-wave time point, and duration of modulated pump speed cycle
(% systole or % diastole). In this study, the intelligent control system was tested using a
clinical grade LVAD (HVAD, Medtronic, Minneapolis, MN). The HVAD is a continuous
flow centrifugal blood pump with a therapeutic window of 1,800 – 4,000 rpm as specified
by Medtronic’s instructions for use (IFU).
The control algorithm used to modulate HVAD pump speed was developed by
Dr. Richard Wampler (Oregon Health Sciences University, Portland OR), which is
currently protected by provisional patent (proprietary), and was implemented using
LabVIEW (National Instruments, Austin, TX). A high-fidelity EKG waveform (1kHz)
from a Patient Simulator (Fluke Biomedical, Everett, WA, medSim 300B) and R-wave
detection algorithm were used to trigger an increase (or decrease) in HVAD pump speed
by increasing (or decreasing) the current supplied to the HVAD. The software program
provided the following user-defined input parameters via a graphical user interface
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(GUI): (1) R-wave detection threshold (V), (2) low and high pump speeds (rpm), (3) time
delay after successful R-wave detection to initiation of pump speed modulation sequence
(ms), and (4) systolic duration (%). In addition, the GUI continuously displays in realtime the EKG waveform, R-wave trigger landmark, and pump speed. The key
components of the intelligent LVAD control system are shown in Figures 10 and 11.

Figure 10: Medtronic HVAD centrifugal blood pump (Medtronic, Minneapolis MN). The HVAD is a
continuous flow LVAD that operates at a clinical therapeutic window of 1,800-3,200 RPM as stated by
HeartWare IFU (TOP). Intelligent controller (hardware) that has connections for the HVAD, a current
measurement, and EKG input. (BOTTOM) The controller interfaces with the HVAD and intelligent
control algorithm to allow the algorithm to visualize the EKG and detect the R-wave trigger. The
algorithm then interfaces with the controller to increase (or decrease) pump speed based on R-wave
detection with an additional output connection to measure the current being delivered to the HVAD
(pump speed increase (or decrease)).
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Figure 11: Front panel display of Graphical User Interface (GUI) of intelligent control software, including two waveform graphs that plot commanded RPM
(top) for the HVAD to operate at and EKG waveform (bottom). The command RPM waveform has two indicators (1) command RPM to be sent and (2) the
detected RPM of the HVAD. The EKG waveform has three indicators one for the detected EKG in volts, another for detected QRS peak in volts, and finally
detected QRS frequency in hertz to determine beat rate of signal. The GUI has five controls for operating the HVAD (1) a stop VAD command to stop the
HVAD, (2) a manual RPM if the HVAD was to be run in a fixed speed, (3) systolic RPM to operate the HVAD, (4) diastolic RPM to operate the HVAD, and
(5) percent systole that determines how long the HVAD should operate at the systolic RPM. A threshold control is set to lower (or increase) the peak
detection voltage to allow only the R-wave to trigger increase (or decrease) pump speed while in operating in a pulsatile manner.

2.

Intelligent LVAD Control Operation

The intelligent control strategy was tested using an HVAD with left ventricular
apical inflow and aortic outflow cannulation in the MCL model during a simulated HF
test condition. Baseline hemodynamics were recorded with the HVAD off and outflow
graft clamped before and after data epoch to confirm minimal (non-significant) changes
in the HF test condition. Hemodynamic data were recorded with HVAD operated at fixed
pump speeds (1500, 2000, 2500, 3000, 3500, 4000 rpm) and with pump speed
modulation, each operating setting tested during this experiment is listed in Table IV.
During pump speed modulation, the intelligent controller was set to a low pump speed
(1500 rpm), high pump speeds (2500, 3000, 3500, 4000 rpm), and systolic (or diastolic)
durations (30%, 35%, 40%), as illustrated in Figure 9. The operating range of high and
low pump speeds was determined by using the therapeutic window (1,800-4,000 rpm)
specified by the HVAD IFU. The pump speed modulation (Drpm) was defined as the
difference between low and high pump speed settings (i.e. low = 1500 rpm, high = 4000
rpm, Drpm =2500rpm). The intelligent LVAD control strategy was triggered from an
EKG simulator at a constant beat rate of 80 BPM, while the MCL artificial ventricle was
set at a beat rate of 78 BPM. This slight offset allowed for asynchronous operation of the
intelligent LVAD control strategy, which gave multiple phases of purely asynchronous
support, phases of co-pulsation support, and phases of counter-pulsation support over a
four-minute test run (single data file). A single four-minute epoch (n=1) was recorded
once for each pump setting. The order of data acquisition was fixed speed, 30% systolic
duration, 35% systolic duration, and 40% systolic duration operating settings (note: order
was not randomized).
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TABLE IV: EXPERIMENTAL DESIGN OF INTELLIGENT
LVAD CONTROL STRATEGY EXPERIMENT
Table IV. Study design of intelligent LVAD control strategy experiment. A mock
circulatory loop (MCL) tuned to simulate class IV heart failure (HF) to (1) determine the
capability of pump speed modulation within a single cardiac cycle, and (2) evaluate the
hemodynamics achieved while operating the intelligent LVAD control strategy
asynchronously with phases of co-pulsation and counter-pulsation. To accomplish these
two objectives the intelligent LVAD control strategy operated a HeartWare HVAD at fixed
speed and then at various Drpm and systolic durations (30%, 35%, and 40%). Systolic
duration corresponded to the amount of time spent at the lower operating pump speed
(1,500 rpm) during each cardiac cycle while the Drpm represents the difference between
high and low pump speed. Each operating condition was recorded once with a four-minute
data file (n=1).
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3.

Mock Loop Model

A MCL was developed to simulate the hemodynamics of a NYHA class IV HF
patient. The MCL was primed with a blood analog solution of glycerol (Fisher Scientific,
G33-4, Lot 180512)-saline to simulate a viscosity range of 3.0±0.2 cP to represent a
hematocrit of approximately 38%. Saline was created at a concentration of 0.9% using
distilled water and sodium chloride (Fisher Scientific, L-11635). A hematocrit of
approximately 38% was chosen to mimic the hemodilution that occurs in patients
diagnosed with HF resulting from an increased plasma volume (Androne et al., 2003;
Guglin et al., 2012). The viscosity of the solution was tested before the first test condition
and repeated after completion of last test condition to validate that the viscosity did not
change significantly over the entire time-course of the study. A viscometer (“Q” Glass
Company, Inc., Towaco, NJ) and water bath (Thermo Scientific, Marietta, OH) were used
to test the viscosity of the solution at 37°C by recording the transit-time of the solution
through the viscometer. The viscosity of the solution was derived from the relationship
between the viscosity constant, transit time, and density of the solution, as defined in
Equation 1.

"#$%&$#'( = 0.00743 ∗ '012$#' '#45 ($5%&27$) ∗ 752$#'(

The MCL was configured to simulate an adult single-sided systemic (high
pressure) circulation with the following major components: (1) volume reservoir to
simulate venous return, (2) inflatable balloon to simulate the compliance of the left
atrium, (3) arterial compliance chamber, (4) pneumatically-actuated silicone sac to
simulate the left ventricle, and (5) silicone tubing (1/8” to 3/4” inner diameter) to
36

(1)

simulate the aorta (Figure 12). A Sarns cardiopulmonary bypass machine (Terumo,
Somerset, NJ) and a Sarns heater-cooler were used to maintain a physiologic temperature
of 37°C of the blood analog solution. The construction of the MCL is representative of a
lumped parameter model, and thereby assumes minimal losses compared to a distributed
(network) model or human anatomic structure.

1

7
5
2

4

3

6
Figure 12. The mock circulatory loop (MCL) used to test the intelligent HVAD control system
consisted of a (1) volume reservoir, (2) artificial left atrium, (3) artificial ventricle, (4) arterial
compliance chamber, (5) 1/8” to ¾” silicone tubing to simulate aorta, (6) HVAD insert into apex of
artificial ventricle, (7) and peripheral resistor clamp to adjust afterload.
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4.

Hemodynamic Measurements & Data Acquisition

Data acquisition (DAQ) and LabChart (AD Instruments, Version 8, Colorado
Springs, CO) were used for signal conditioning (Koenig et al., 2004), real-time A/D
conversion (400 Hz sampling rate, 100 Hz low pass filter), visual display, and recording
of 11 hemodynamic parameters, as shown in Figure 13. Signal conditioning of the left
ventricular pressure (LVP) and aortic pressure (AoP) distal waveforms was performed
using a 10 Hz low pass filter (LabChart, finite impulse response (FIR)) to reduce the
signal noise recorded produced by the mechanical valve used in the mock loop model to
simulate the aortic valve. Similarly, a low pass filter of 40 Hz was applied to the current
waveform to reduce the electrical noise. The EKG waveform was amplified to an R-wave
peak of ~2.5 volts to enable reliable threshold detection by the programmed intelligent
control algorithm. A medSim 300B patient simulator was used to produce an EKG at a
heart rate of 80 BPM to test the intelligent HVAD control system R-wave detection and
pump speed modulation algorithms. Each intelligent LVAD control strategy pump
operating setting was recorded using four-minute epochs to allow for phases of
asynchronous, co-pulsation, and counter-pulsation support.
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Figure 13. Data acquisition system (DAQ) with LabChart software
used throughout the experiment to record hemodynamic waveforms.

Left atrial pressure (LAP) was measured using a low-fidelity (20 Hz) fluid-filled
catheter (ARGON, Frisco, TX) and cardiac care patient monitor (Agilent, Santa Clara,
CA). Left ventricular (LV), distal aortic pressure (AoP), and LVAD pressures were
measured using single-tip, high-fidelity (5kHz) catheters (Millar, Houston, TX). Aortic
root flow (AoF), total flow (TF), and VAD flow (VADF) were measured using highfidelity (100Hz) transit-time flow probes (Transonic Systems, Ithaca, NY). Left
ventricular pressure-volume loops were measured using a pressure-volume admittance
catheter (Transonic Systems, 5F, 4 segments, 10mm spacing).
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Fluid-filled catheters were open to atmosphere and zeroed using the cardiac care
patient monitor and calibrated using a TruCal Simulator/Tester (Baxter, Tulsa, OK) over
a clinically-relevant range of pressures (-5 to 150 mmHg). Millar pressure catheters were
pre- and post-calibrated using a digital manometer (Meriam, Cleveland, OH) and
pressure chamber over a clinically-relevant range of pressures (-5 to 150 mmHg). Flow
probes were pre-calibrated electronically using a flow module calibration step (0 volt to
1-volt (full-scale)) and factory calibration settings based upon flow probe size, mock loop
tubing diameter, and style (in-line, clamp-on). Sample pressure and flow sensor
calibration sequences are illustrated in Figure 14.

Figure 14. Illustration showing flow probe and pressure
transducer electrical calibration. Flow probes were
electrically calibrated using built in electrical calibration
from flow module based on flow probe size and tubing
diameter. Pressure transducers were calibrated by
creating a known pressure in a pressure chamber (-5 to
150 mmHg) and then correlating each electrical signal
with its corresponding pressure.
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The pressure-volume admittance catheter was calibrated using internal electronic
calibration settings programmed into the ADVantage PV system (Transonic, ADV500; 0
to 400 mL, phase 0 to 20°, and mag 0 to 50 mS). The stroke volume input was set prior to
the baseline HF recording for each set of data recordings (Table V) and was calculated by
dividing the measured cardiac output by the beat rate of the artificial ventricle. Pre- and
post-calibrations were completed for all sensors and signal conditioners to verify gain and
offset were consistent (i.e. no significant drift). Intrinsic pump parameters that were
recorded directly and/or derived during post-processing, included current, pump speed
(rpm), and power. The hemodynamic parameters recorded throughout the intelligent
LVAD control strategy experiment and the instrumentation used to acquire each
parameter in this study are listed in Table V. The placement of each sensor within the
MCL model for recording each of the eleven hemodynamic parameters is illustrated in
Figure 15.
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Abbreviation
EKG
LVP
LAP
VADP
AoF
LVAD Flow
AoP Distal
TF
A
LVV
RPM

Instrument
Patient Simulator
Millar Catheter
Fluid Filled Transducer
Millar Catheter
Transonic Flow Probe
Transonic Flow Probe
Millar Catheter
Transonic Flow Probe
Intelligent Controller
Transonic PV Catheter
Intelligent Controller

Table V. Hemodynamic parameters recorded during intelligent LVAD
control strategy experiment. The abbreviation, instrument used to record
each parameter, range, and unit of each parameter recorded is listed above.

Parameter
Electrocardiogram
Left Ventricular Pressure
Left Atrial Pressure
VAD Pressure
Aortic Root Flow
Left Ventricular Assist Device Flow
Aortic Pressure Distal
Total Flow
Current
Left Ventricular Volume
Pump Speed

TABLE V
HEMODYNAMIC PARAMETERS RECORDED DURING
INTELLIGENT LVAD CONTROL EXPERIMENT

Range
-0.2-3
-5-150
0-30
0-150
0-4
-1-10
0-150
0-6
0-2
0-400
0-4000

Unit
Volts
mmHg
mmHg
mmHg
L/min
L/min
mmHg
L/min
Amps
mL
RPM

LA: Left Atrium
LAP: Left Atrial Pressure
LV: Left Ventricle
LVP: Left Ventricular Pressure
LVV: Left Ventricular Volume

VADP: LVAD Pressure
VAD Flow: LVAD Flow
AoF: Aortic Flow
AoP Distal: Distal Aortic Pressure

Figure 15. Schematic of mock circulatory loop (MCL) with location of each hemodynamic
parameter recorded during the intelligent LVAD control strategy experiment.

The MCL was constructed and tuned to simulate hemodynamics of NYHA class
IV HF (Yildiran et al., 2010; Melenovsky et al., 2015) with the mock LV heart rate set at
80 bpm, systolic duration of 35%, and cardiac output of 3 L/min representative of the
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values seen in class IV HF patients with body mass index (ratio of weight to height:
(kg/m2)) and cardiac index (assessment of cardiac output with respect to patients size)
(Carlsson et al., 2012). The MCL was tuned by adjusting the preload (atrium), source
(ventricle), and afterload (vasculature). The preload of the MCL was set by adjusting the
height of the venous reservoir, as well as increasing the total volume of the reservoir until
the LA pressure was within the target clinical range. The silicone mock LV pneumatic
drive (positive) and vacuum (negative) pressures, percent systole, and beat rate were set
using a clinical-grade pneumatic driver (P/N 500099-0006-005E Thoratec, Pleasanton
CA). Afterload of the MCL was set by increasing (or decreasing) the peripheral
resistance of the MCL by the closing (or opening) the turn-screw clamp (resistor) placed
on the aorta and before the venous reservoir.

5.

Data Analysis

Data were analyzed on a beat-to-beat basis with the recorded time period to
quantify the hemodynamic performance of operating the intelligent LVAD control at
fixed speed or in a pulsatile manner and test the proposed hypothesis that pump speed
modulation provides improved hemodynamic support compared to HF baseline (pump
off) and fixed pump speed. Data recorded using the intelligent control strategy to induce
pump speed modulation were parsed into co-pulsation and counter-pulsation segments for
each recorded four-minute asynchronous data file and each operating condition (i.e. 30%
systolic duration at a D1000 rpm, n=1), as listed in Table IV. By operating the artificial
ventricle at a beat rate of 78 BPM and triggering pump speed modulation using the
intelligent LVAD control strategy at a beat rate of 80 BPM, phases of asynchronous, copulsation, and counter-pulsation support were achieved in a single data file (as opposed to
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recording three separate data files for each phase of support). To determine co-pulsation
and counter-pulsation beat segments, the increase (or decrease) in pump current was
aligned with the corresponding landmark of the LVP waveform. For the co-pulsation beat
segment, a beat with an increase (or decrease) in LVAD current aligned with the
beginning of systole, and the beats before and after were selected to create a three-beat
co-pulsation segment. For counter-pulsation beat segments, a beat with an increase (or
decrease) in LVAD current aligned with the end of systole, and the beats before and after
were selected to create a three-beat counter-pulsation segment. These segments were then
analyzed to quantify the hemodynamic performance during fixed speed, co-pulsation, and
counter-pulsation to investigate their effect on ventricular volume unloading, cardiac
output, and pulsatility. The hemodynamic waveforms were also graphed to evaluate the
ability of the intelligent control strategy to modulate pump speed within a cardiac cycle.
Data were normalized by averaging the pre- and post-calibrations of all pressure,
flow, and volume measurements. Pre- and post-calibrations were averaged to mitigate
any electrical drift that may have occurred during the experiment. Although minimal
electrical drift was seen between the pre- and post-calibrations for each parameter, the
average was still used to create the calibration factor in LabChart for each parameter
recorded during the experiment. Once normalized, the hemodynamic data were exported
from LabChart into text files. These texts files were saved as DAT-files, and imported
into MatLab (R2016, Mathworks, Natick, MA) for post-processing and data reduction
using a Hemodynamic Estimation and Analysis Research Tool (HEART) software
(Schroeder et al., 2004). Once imported into the HEART program, each data file was
“beat picked” using the LVP as the reference signal and a “beat picking method” that
selected end-diastolic landmark using a threshold detection and slope algorithm, as
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previously reported (Schroeder et al., 2004). This point on the LVP waveform
corresponds to end diastole was used as the reference point for starting and ending each
beat. The reference point was selected using an upper threshold, a lower threshold, a bad
beat threshold, and an end-diastolic threshold. Sample LVP and AoP distal waveforms
with each beat start and end point landmark identified by a red circle on the LVP
waveform is shown in Figure 16.
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Figure 16. Hemodynamic Estimation and Analysis Research Tool (HEART) with left ventricular pressure (LVP, green waveform) and aortic pressure
(AoP distal, red waveform) waveforms. Beginning and end of each beat are depicted by red circle on the LVP waveform corresponding to end diastole.
Beginning and end of each beat were selected using an upper threshold, lower threshold, and end diastolic threshold.

Once each data file was “beat picked”, the file was exported as a MAT-file for
analysis by a custom MatLab script as listed in Appendix III. The MatLab script was
used to analyze beat-to-beat parameters for each of the 12 recorded hemodynamic
waveforms. The script was able to produce calculations, including max-min flow, maxmin pressure, as well as mean pressures and flows during each part of the cardiac cycle
(systole-diastole).
Pulse pressure (∆P), mean arterial pressure (MAP), surplus hemodynamic energy
(SHE), energy equivalent pressure (EEP), and arterial impedance (ZART) were
calculated from the recorded hemodynamics to quantify the impact the intelligent HVAD
control system had on pulsatility. EEP is defined as the hemodynamic energy of a given
volume of fluid passing through a given tubing cross section as expressed by Equation 2
(Soucy et al., 2013).
::; =

∫ = ∗ ; ∗ 7'
∫ = ∗ 7'

(2)

SHE is defined as the additional energy that exists when there is some degree of
pulsatility in the pressure or flow waveform (Ündar et al., 2005), SHE is represented as
the difference of EEP and MAP multiplied by 1,332 (Equation 3).
>?: (50@$/%4B ) = 1,332 ∗ (::; − GH;)

(3)

ZART (vascular load impedance) is a function of resistance, compliance, and
inertance, and regulates the dissipation of hemodynamic energy (Soucy et al., 2013).
ZART is expressed as the fast Fourier transform (FFT) of arterial pressure divided by the
FFT of arterial flow (Equation 4). For this experiment the resistance component of ZART
was analyzed and is the quotient of mean pressure divided by mean flow.
IJKL =

MMN(;)
MMN(=)
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(4)

LV stroke volume, LV external work (PV loop area), LV end diastolic pressure,
and LV end systolic pressure were calculated to determine the effect of the intelligent
LVAD control strategy had on ventricular volume unloading. Intrinsic pump parameters
including speed (rpm) and current were recorded from the intelligent controller and
analyzed. Power was calculated by multiplying the current and voltage supplied to the
HVAD during pump operation. These parameters were used in correlation with
hemodynamic data to visualize trends associated with increasing (and decreasing) flows
and pressures during pump speed modulation with each cardiac cycle. Data are presented
as means and percent differences between equivalent means for pump power comparison.
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III.

RESULTS

A. Key Findings
In this study, we successfully demonstrated that a novel intelligent LVAD control
algorithm was able to increase and decrease the operating pump speed (rpm) of a
Medtronic HVAD within a single cardiac cycle using an EKG waveform and R-wave
threshold detection algorithm to trigger changes in pump speed. In addition, we identified
two distinct time delays associated with the intelligent control strategy: (1) a time delay
with initiation of changes in pump speed limitations associated with the R-wave detection
and trigger algorithm(s), and (2) a hemodynamic time delay that occurs between the
increase in pump speed and the increase in LVAD flow associated with fluid inertia. We
also identified that improvements in hemodynamics with increasing levels and timing of
pump speed modulation came at the expense of increased LVAD power consumption
compared to operating at fixed speeds with equivalent mean flows. Notably, pump speed
modulation improved hemodynamic performance as evidenced by dynamic LV volume
unloading, increased cardiac output, and increased pulsatility with higher mean pump
speed operating settings producing the greatest increases in LV volume unloading and
cardiac output in this study, and the lower mean pump speed operating settings producing
the greatest increases in pulsatility indices.

B. Mock Circulatory Loop (MCL) Model
We successfully demonstrated that the MCL model, used to test the performance
of the intelligent LVAD control system, closely matched the blood viscosity and
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hemodynamic waveforms and landmark parameters of a NYHA class IV HF patient
(Table VI), and the viscosity of the blood analog solution was maintained at a mean of
3.01 cP and differences between pre- (3.05 cP) and post-calibrations (2.97 cP) were
negligible.
TABLE VI
COMPARISON OF CLINICAL CLASS IV HEART FAILURE AND MOCK
CIRCULATORY LOOP ACHIEVED HEMODYNAMICS

Comparison of Hemodynamic Paremeters
Parameter
Clinical Class IV HF
Systolic Blood Pressure (mmHg)
98 ± 12
Mean Arterial Pressure (mmHg)
77 ± 9
Diastolic Blood Pressure (mmHg)
66 ± 8
Aortic Pulse Pressure (mmHg)
31 ± 9
Ejection Fraction (%)
25 ± 5
Cardiac Output (L/min)
<3
Left Atrial Pressure (mmHg)
20 ± 8
Heart Rate (BPM)
92 ± 15

MCL Achieved
84
63
46
38
23
3
23
78

Table VI. Clinical presentation of class IV heart failure hemodynamic parameters
compared to achieved hemodynamics in mock circulatory loop. Clinical
hemodynamic parameters are represented as mean +/- standard deviation (Yildiran et
al., 2010; Melenovsky et al., 2015).

C. Intelligent LVAD Control –Engineering and Hemodynamic Performance
1.

Pump Speed Modulation – Engineering Benchmarks

The intelligent LVAD control system successfully demonstrated the ability to
rapidly increase and decrease HVAD pump speed within a single cardiac cycle during
asynchronous operation, which also produced phases of synchronous co-pulsation and
synchronous counter-pulsation profiles for all systolic durations (30, 35, 40%) at the
highest pump speed profile (Drpm = 2500), as shown in Figure 17. Specifically, the Rwave threshold detection algorithm demonstrated the ability to trigger an increase (or
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decrease) in HVAD pump speed (by the change pump current as represented by the
dotted vertical line for each beat) and decrease (or increase) in pump speed for specified
systolic duration prior to the next cardiac cycle (EKG waveform – QRS complex). Key
observations during the pump speed modulation study include the following: (1) pump
speed (current) operated independently of LV end-systole or end-diastole during periods
of asynchronous support, (2) during periods of synchronous co-pulsation pump speed
(current) increased at LV end-diastole, (3) during periods of synchronous counterpulsation pump speed (current) increased at LV end-systole, and (4) when R-wave
detection is missed the pump speed remains at the higher operating speed until the next
R-wave is detected. Sample asynchronous, synchronous co-pulsation, and synchronous
counter-pulsation waveforms for all controller settings (systolic duration, Drpm) are
presented in Appendix I.
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Figure 17. Asynchronous data recordings while operating the intelligent HVAD control at a D2500 RPM. Asynchronous beat-to-beat hemodynamic waveforms
occur when increase (or decrease) in pump speed does not correlate with LV end-diastole or LV end-systole. Co-pulsation (red circle) beat-to-beat
hemodynamic support occurs when pump speed increases (or decreases) at LV end-systole resulting in an increase in pulse pressure and LVAD flow. Counterpulsation (blue circle) hemodynamic support occurs when pump speed increases (or decreases) at LV end-diastole and an increase in diastolic LVAD flow and
a lowering of the LV end-diastolic pressure is seen. Missed R-wave detection is seen (black circle) with pump speed remaining at highest operating speed until
next R-wave detection. Co-pulsation, counter-pulsation, asynchronous, and missed R-wave detection were consistent across all Drpm and systolic durations
(30%, 35%, 40%) tested. EKG: electrocardiogram, LVP: left ventricular pressure, AoP: distal aortic pressure, LVAD Flow: left ventricular assist device flow,
Current: HVAD current (I, amps).

2.

Time Delay

Two distinct time delays were observed during pump speed modulation with the
intelligent LVAD control system: (1) a delay in pump speed modulation despite accurate
R-wave threshold detection, and (2) a delay in increase in LVAD flow due to the fluid
inertia of the blood analog solution in the MCL.
a. R-Wave Trigger Time Delay
Ideally, the intelligent control would increase (or decrease) the HVAD pump
speed (current, dotted vertical line, Figure 19) instantaneously upon R-wave detection;
however, a time delay between detection of the R-wave and trigger to initiate increase (or
decrease) of pump speed for systolic durations of 35% and 40% (Figure 18, Figure 19)
being 45 ± 3.0 ms and 82 ± 3.0 ms (Figure 16) was identified.

Figure 18. A time delay between detection of the R-wave trigger and
subsequent pump speed modulation was seen while operating the intelligent
LVAD control strategy at systolic durations of 35% and 40%. The data
presented is displayed as the mean.
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Figure 19. The graphs above show MCL-acquired counter-pulsation and co-pulsation hemodynamic waveforms
for a D2500 RPM across the 30, 35, and 40% systolic durations tested. The R-wave trigger is depicted as a vertical
dotted line overlaying the R-wave. The time delays for 35% and 40% systolic durations are depicted as the red
area 45 ms and 82 ms, respectively, after the R-wave.
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b. Fluid Inertia Time Delay
Additionally, a time delay between initiating the increase (or decrease) in pump
speed and the resulting increase (or decrease) in LVAD flow was identified during copulsation and counter-pulsation phases (Figure 20). We hypothesize that this time delay
may be associated with an inertial effect to rapidly increase (or decrease) blood flow
(Figure 21). The flow inertia delays were 35 ms and 187 ms for co-pulsation and counterpulsation, respectively. The inertia delay will also likely be a function of patient
physiologic condition (ex. during hypervolemia, hypovolemia, etc).

Figure 20. A time delay was observed between initiating the
increase (or decrease) in pump speed modulation and the
subsequent increase (or decrease) in LVAD flow for phases of
co-pulsation and counter-pulsation support. The data presented
is displayed as the mean.
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Figure 21. Hemodynamic waveforms for the D2500 rpm at a systolic duration of 40% operating setting to visualize
the time delay created from the fluid inertia of the blood analog solution used in the mock circulatory loop. The
fluid inertia delay is the delay between the increase (or decrease) in pump speed and the resulting increase in
LVAD flow. The fluid inertia time delay is visualized as the red hued area on the waveform graph and varied
between phases of co-pulsation (35 ms) and phases of counter-pulsation (187 ms) support. P

3.

Slew Rate

The pump speed slew rate was calculated for each Drpm operating setting. The
pump speed slew rate is defined in classical engineering textbooks as the change in
electrical current per unit time. In this study, the pump speed (rpm) was initially assumed
to correlate with the electrical current; however, this relationship was shown to be nonlinear (Figure 22). The ability to rapidly increase (or decrease) within a cardiac cycle is
an important design criteria, especially with increasing heart rate, which is shown in
Figure 22. The D2500 rpm demonstrated the most rapid change in pump speed (88.5
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rpm/ms). The current slew rate (Figure 22) was also calculated and showed that the
highest slew rate of 49 Amps/sec was achieved while operating the intelligent LVAD
control at a D2500 rpm. The current slew rate increased with each increasing Drpm
testing condition similar to the pump speed slew rate which is expected as current is the
input to the LVAD that controls which speed the device is operating. In this study we
demonstrated the ability to rapidly increase (or decrease) pump speed to achieve the
desired Drpm target values.
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Figure 22. Pump speed slew rate (top) and current slew rate (bottom) were
calculated to evaluate if the intelligent LVAD control strategy had the
ability to increase the rate at which pump speed is modulated at higher
Drpm operating settings. The slew rate increased for each increase in
Drpm resulting in the ability of the intelligent LVAD control strategy to
modulate pump speed and current within a single cardiac cycle while
operating at either high or low pump speed. The data presented is
displayed as the mean.
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D. Intrinsic Pump Parameters
Intrinsic pump parameters (HVAD pump speed, current, and power usage) were
obtained for all recorded test conditions. HVAD pump speed and current were recorded
to confirm that HVAD pump speed was increasing (or decreasing) in response to
increasing (or decreasing) the current supplied by the HVAD controller to the pump.
HVAD power usage was recorded to evaluate if there was a penalty of increased power
consumption while operating the HVAD in a pulsatile manner using the intelligent
LVAD control strategy. Our results demonstrate that HVAD pump speed did increase (or
decrease) in response to increasing (or decreasing) current and that there was a penalty of
increased power usage when operating the HVAD in a pulsatile manner when compared
to fixed speed operation at equivalent mean pump speeds (Table VII).
1. Mean HVAD Pump Speed
Mean LVAD pump speed was recorded throughout the duration of the experiment
when operating the HVAD using the intelligent LVAD control strategy, as shown below
in Figure 23. The highest mean pump speed while operating the HVAD using the
intelligent control strategy in a pulsatile manner was during 30% systolic duration at a
D2500 rpm. The mean pump speed was determined to not only be a function of the Drpm,
but also a function of the systolic duration (or the time spent at each high and low
operating setting), which can be visualized by the lowered mean pump speed with
increasing systolic duration that corresponds to a shorter time spent at the higher
operating rpm. Corresponding mean fixed speeds, depicted as horizontal red dotted lines,
are also shown in Figure 23. Additionally, individual mean rpm values for each pulsatile
operating setting tested using the intelligent LVAD control strategy were plotted with the
red line depicting the mean of the data set. This graph shows the overshoot (or
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undershoot) that occurs when operating the HVAD in a pulsatile manner with the
intelligent LVAD control strategy. The two distinct clusters of mean rpm data points
above and below the overall mean rpm represent the overshooting (or undershooting) of
the desired operating rpm during pump speed modulation.
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Figure 23. Mean pump speed (top) was plotted for each Drpm and systolic duration. Mean pump
speed increased with increasing Drpm and was the highest at 30% systolic duration for each Drpm.
The red dashed line (top) represents the fixed pump speed the HVAD was operated at during the
intelligent LVAD control strategy experiment. Mean pump speed (bottom) was plotted as individual
values on a beat-to-beat basis to show undershoot and overshoot of pump speed modulation
throughout the entire four-minute data recording during pulsatile operation using the intelligent
LVAD control strategy. Clusters above and below overall mean pump speed (red line, bottom graph)
represent the over- and undershoot of the desired pump speed while operating in a pulsatile manner
using the intelligent LVAD control strategy. It was determined that mean pump speed is not solely a
function of the high and low pump speed settings but also as a function of the time spent (systolic
duration) at the high and low pump speeds. Data is presented as the mean for the top graph and
individual means for each ventricular beat on the bottom graph.
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2. HVAD Current
The current supplied to the HVAD from the intelligent controller was recorded
throughout the experiment. As expected, the current increased with increasing pump
speed operation (Figure 24). The current supplied to the HVAD is the input that either
increases (or decreases) pump speed during operation. The highest current recorded
during the pulsatile operation of the intelligent LVAD control strategy was during 30%
systolic duration at a pump amplitude of D2500 rpm, which corresponds with the highest
mean pump speed setting. Current also decreased with increasing systolic duration,
corresponding to a lower total time spent at the higher rpm during pulsatile operation. As
seen in the individual data point graph (Figure 24) the overshoot (or undershoot) of the
current corresponded to the intelligent LVAD control strategy either over (or
undershooting) the desired pump speed while operating the HVAD in a pulsatile manner.
Also shown in Figure 24, the current and increasing pump speed (rpm) was not
linear when operating the HVAD using the intelligent LVAD control strategy. It would
have been expected that by increasing the magnitude of pump speed by 500 rpm each
operating setting that the current magnitude would have increased linearly with respect to
pump speed, due to current being the input that controls pump speed. Also, the current to
power relationship is more curvilinear than the current to rpm relationship due to power
being derived by squaring the current and then multiplying it by the internal coil
resistance of the HVAD.

63

Figure 24. Mean current (top) supplied to the HVAD was plotted for each Drpm and systolic
duration during pulsatile operation and at each fixed speed operating setting during
continuous operation. Mean current supplied to the HVAD increased with increasing Drpm
and was the highest at 30% systolic duration for each Drpm and follows the same trend as
mean pump speed. Current supplied to the HVAD is the input that dictates what pump speed
the LVAD will operate at. Mean current (bottom) supplied to the HVAD was also plotted as
individual values on a beat-to-beat basis to show over- and undershoot of current supplied to
the HVAD during pump speed modulation throughout the entire four-minute data recording
for each pulsatile operating setting. As seen in the bottom graph continuous operation does
not demonstrate any over- or undershoot of current supplied to the HVAD, but while
operating in a pulsatile manner the clusters of data above and below the overall mean current
(red line, bottom graph) indicate an over- or undershoot of current supplied to the HVAD
during pump speed modulation. Data is presented as the mean for the top graph and
individual means for each ventricular beat on the bottom graph.

64

3. HVAD Power
The power of the HVAD during this experiment was derived by multiplying the
current squared by the internal resistance of the HVAD pump used in this study. The
internal coil resistance of the HVAD was 4.8 ohms and was multiplied by the current
squared that was supplied to the HVAD to acquire total estimated power. HVAD power
usage on average was greater while operating in a pulsatile manner using the intelligent
LVAD control strategy when compared to mean pump speeds at equivalent mean pump
flows (Table VII) with the exception of operating the intelligent control strategy at a
systolic duration of 40% with D2000 and D2500 rpms. This could be explained due to
these two operating settings not corresponding exactly to a fixed speed operating setting
tested in this experiment. Power followed the same trend as mean pump speed, and
current with the higher the Drpm had the higher power requirement compared to systolic
durations (Figure 25). By plotting the data points individually, we are able to demonstrate
intelligent LVAD control over- and undershooting desired operating pump speed (Figure
25) leading to a larger range of power use when compared to fixed speed operation. By
correcting this over (or undershoot) of pump speed while in pulsatile operation, the power
difference between pulsatile operation and corresponding fixed speed mean pump speed
may be reduced and the percent increase in pump power decreased while operating in a
pulsatile manner.
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Figure 25. Mean HVAD power usage (top) was plotted for Drpm and systolic duration during
pulsatile operation and at each fixed speed operating setting during continuous operation.
Mean HVAD power usage increased with increasing Drpm and was the highest at 30%
systolic duration for each Drpm and follows the same trend as mean pump speed and current
supplied to the HVAD. HVAD power usage on average is higher during pulsatile operation
while modulating pump speed using the intelligent LVAD control strategy when compared to
an equivalent mean pump speed. Mean HVAD power usage (bottom) was also plotted as
individual values on a beat-to-beat basis to show over- and undershoot of HVAD power usage
during pump speed modulation throughout the entire four-minute data recording for each
pulsatile operating setting. As seen in the bottom graph continuous operation does not
demonstrate any over- or undershoot of power usages, but while operating in a pulsatile
manner the clusters of data above and below the overall mean HVAD power usage (red line,
bottom graph) indicate an over- or undershoot of HVAD power during pump speed
modulation. Data is presented as the mean for the top graph and individual means for each
ventricular beat on the bottom graph.

66

TABLE VII
POWER DIFFERENCE BETWEEN PULSATILE OPERATION USING THE INTELLIGENT
LVAD CONTROL STRATEGY AND EQUIVALENT FIXED SPEED MEAN RPM

Power Difference

30%

35%

40%

Δ1000
Δ1500
Δ2000
Δ2500
Δ1000
Δ1500
Δ2000
Δ2500
Δ1000
Δ1500
Δ2000
Δ2500

Percent Change (%)

Equivalent Fixed Speed (RPM)

46
26
13
12
37
18
6
3
32
6
-4
-5

2000
2500
3000
3500
2000
2500
3000
3500
2000
2500
3000
3500

Table VII. Power usage difference of each pulsatile operating setting compared to its
equivalent mean fixed pump speed operating setting. Power usage on average was higher for
pulsatile operation when compared to continuous operation of the HVAD using the intelligent
LVAD control strategy. The negative power usage difference for D2000 and D2500 while
operation at a systolic duration of 40% may be attributed to these settings not having a true
equivalent fixed speed to compare against, as these two settings mean pump speeds lying in
between the fixed speed operating settings tested. Data is presented as the percent difference
between pulsatile operating settings and equivalent fixed speed operating settings.

E. Pump Speed Modulation – Hemodynamic Performance
Within a select 10-second data epoch of asynchronous operation phases during
co-pulsation and counter-pulsation support were achieved for single, isolated cardiac
cycles. In between these time points, asynchronous support occurred independent of the
cardiac cycle to produce beat-to-beat changes in hemodynamic parameters. The
hemodynamic support achieved for pulsatility, LV volume unloading, and cardiac output
were determined for each type of support (co-pulsation, counter-pulsation, and fixed
speed). The operating condition that provided the greatest degree of ventricular volume
unloading, highest increase of total and LVAD flow, highest preserved aortic flow, and
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greatest degree of pulsatility with its specific achieved hemodynamic values (Table VIII).
Overall, operating the intelligent control at a D2500 rpm (highest mean rpm) resulted in
the greatest degree of ventricular volume unloading, the highest increase in total flow,
and the highest increase in LVAD flow. The greatest increase in aortic flow and greatest
degree of pulsatility parameters were achieved by operating the intelligent control at a
D1000 rpm (lowest mean rpm).
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TABLE VIII
OPERATING SETTINGS AND HEMODYNAMIC PARAMETERS ACHIEVED USING INTELLIGENT
LVAD CONTROL STRATEGY

Pulsatility

Flows

Volume Unloading

Table VIII. Operating settings for the greatest degree of ventricular volume unloading, increase in total flow
and LVAD flow, and greatest degree of pulsatility are shown on the left side of the table with the
hemodynamics achieved for each operating setting listed on the right side of the table. Operating settings that
have higher mean pump speeds produced the greatest degree of ventricular volume unloading and increases in
total and LVAD flow. Operating settings that have lower mean pump speeds produced the greatest degree of
pulsatility and greatest forward flow through the aortic valve. Data is presented as the mean.
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1.

Left Ventricular (LV) Volume Unloading

Stroke volume decreased for all HVAD pump speed modulation operating
conditions compared to baseline (HF, HVAD off) as shown in Figure 26. However, our
experimental findings did not demonstrate the large reductions in LV unloading we had
hypothesized (smallest stroke volume, achieved at 4000 rpm fixed speed). This may have
been due in part to a significant error associated with LV volume measurement we
identified during data analysis and troubleshooting. This error as well as a potential
calculation error (MatLab script, Appendix III) likely resulted in erroneous LV external
work (equals DLV volume * DLV pressure) results. First error, the LV volume
admittance catheter did not have the required number of segments and appropriate
spacing to accurately measure the volume of the mock ventricle. Second error,
calculation of LV systolic and diastolic pressures (average) and forward flow (LV stroke
volume) may have resulted in an under estimation of these values. To address this error,
we modified our methods and performed additional data analysis using LabChart’s
software. The LabChart calculation of LV external work appeared to be a better
estimation based upon the rough estimation of the area within the PV loop (LV stroke
volume * (LV end systolic pressure – LV end diastolic pressure)).
LV end diastolic pressure was also reduced with increasing mean rpm for all
pump settings (fixed, pulsatile asynchronous operation), as shown in Figure 26.
Additionally, increasing Drpm provides a greater degree of volume unloading during both
phases of co-pulsation and counter-pulsation support (Figure 26), which may also be
attributed to the increase in mean pump speed when increasing Drpm in this study. The
mean pump speed (rpm) for counter-pulsation and co-pulsation is a function of the
systolic duration (time spent at each rpm) and Drpm.
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Pressure-volume (PV) loops recorded for each operating setting tested while
operating the intelligent LVAD control strategy at a fixed speed are shown in Figure 27.
The PV loops did not produce a downward shift to the left as would be expected with
increasing LVAD support for any testing condition (fixed or pulsatile operation). It is
believed that the size of the LV volume catheter used in this study was inadequate and
did not allow for the measuring of LV volume throughout the entirety of the artificial
ventricle. The LV volume catheter limitations may explain (in part) why the end diastolic
and end systolic volumes appear to condense around the center of the NYHA class IV HF
baseline (HVAD off) PV loop.
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Figure 26. Left ventricular stroke volume (right) shows a reduction in stroke volume for all operating
settings during the intelligent LVAD control strategy experiment. Left ventricular end diastolic pressure
(LVEDP, left) indicates a greater degree of volume unloading (reduction in LVEDP) with increasing
DRPM with counter-pulsation having a greater reduction than co-pulsation at equal DRPM. Left
ventricular external work (LVEW, middle) shows a trend of reducing LVEW with increasing DRPM.
Counter-pulsation appears to have the largest reduction in LVEW when compared to co-pulsation at the
same DRPM. Fixed speed is represented on the left side of the x-axis with increasing DRPM progressing
to toward the right side of the x-axis. The data presented is displayed as the mean.

Figure 27. Left ventricular pressure-volume (PV) loops recorded during fixed speed operation
of the HVAD using the intelligent LVAD control strategy. The PV loops for the fixed speed
operation are representative of each operating setting tested during this study. The PV loops
did not shift downward or to the left with increasing LVAD support as would be expected. The
limitations (inadequate of number and spacings of electrodes) of the LV volume catheter used
in this study may explain (in part) why the PV loops did not respond to increasing LVAD
support as would have been expected.

2.

Cardiac Output

As shown in Figure 28, the highest flow was achieved with the HVAD operated at
a fixed speed of 4000 rpm; however, during phases of asynchronous co-pulsation pump
speed modulation at the largest pump speed differential (low = 1500, high = 4000, Drpm
= 2500, systolic duration 30%) mean pump speed was the greatest (3,300 ± 1,200 rpm).
The forward flow at a fixed pump speed of 4,000 rpm was 4.8 L/min compared to a mean
co-pulsation rpm of 4.5 L/min. Mean total flow increased for all pump speed modulation
operating settings with increasing mean rpm and Drpm. Co-pulsation on average yielded
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the highest total forward flow at equivalent mean pump speed (rpm) when compared to
counter-pulsation at the same mean pump speed (rpm). Increasing systolic duration
(lower total time spent at higher rpm) flow decreased due to the reduction in mean pump
speed (rpm), as shown in Figure 28.
The operating setting that had the greatest aortic flow occurred at a D1000 rpm
and a systolic duration of 40%, with phases of co-pulsation having a greater preservation
of aortic flow when compared to phases of counter-pulsation at the same Drpm (Figure
28). Regurgitant flow was seen through the aortic valve when operating the HVAD at
fixed pump speeds greater than 3,500 rpm. In contrast to fixed speed operation of the
HVAD, there was no regurgitant flow observed when modulating pump speed in a
pulsatile manner with the intelligent LVAD control strategy, independent of Drpm or
systolic duration.
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Figure 28. Mean total flow (left) shows greater augmentation of total flow with increasing DRPM for all operating
settings. LVAD flow (right) has the greatest improvement with increasing DRPM as expected across all operating
conditions. Aortic flow (AoF, middle) is diminished with increasing DRPM due to increased LVAD flow, while
operating at fixed speeds of 3,500 and 4,000 rpm AoF is negative due to regurgitation through the aortic valve.
Fixed speed is represented on the left side of the x-axis with increasing DRPM progressing to toward the right side
of the x-axis. The data presented is displayed as the mean.

3.

Pulsatility

Pulse pressure (DP) decreased with increasing mean pump speed (rpm) for all
operating settings (fixed speed and modulating pump speed asynchronously). The
operating setting that achieved the smallest reduction in pulse pressure from HF baseline
occurred at a D1000 rpm and 40% systolic duration, with phases of co-pulsation
producing higher pulse pressures than counter-pulsation at the same Drpm (Figure 29).
The operating setting that resulted in the greatest aortic pressure pulsatility index (PI) was
achieved using the intelligent HVAD control strategy at a D1000 rpm with a systolic
duration of 35%, with phases of co-pulsation producing greater PI than phases of counterpulsation.
SHE, a measure of the extra energy that is produced by pulsatile blood flow, is
reduced in HF patients that are implanted with a CF-LVAD (Soucy et al., 2013). The
operating setting that produced the greatest SHE was at a D1000 RPM at a systolic
duration of 40%, with phases of co-pulsation generating higher SHE values than phases
of counter-pulsation. Vascular resistance was also calculated and increased with
increasing mean rpm from baseline in all operating settings and was higher in copulsation when compared to counter-pulsation at the same mean pump rpm. Increasing
mean pump speed (rpm) decreased pulsatility parameters (Figure 29). When operating at
the same operating setting (equivalent mean pump speed), phases of co-pulsation showed
increases in pulsatility as evidenced by increases in AoP DP, PI, and SHE compared to
phases of counter-pulsation and fixed speed operation.
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Figure 29. Aortic pulse pressure (AoP DP, top-left) reduced with increasing DRPM as expected due to the
subsequent increase in mean pump speed as well. Phases of co-pulsation produced greater pulse pressures than
counter-pulsation and fixed speed operation at equivalent mean pump speeds. Surplus hemodynamic energy
(SHE, bottom-left) reduced with increasing DRPM and followed the same trend as the AoP DP with copulsation producing greater SHE values at equivalent pump speeds. The aortic pressure pulsatility index (PI,
top-right) reduced with increasing operating RPM due to the decrease in AoP DP. Vascular resistance (R,
bottom-right) increased with increasing DRPM with fixed speed operation producing greater vascular resistance
than co-pulsation and counter-pulsation at equivalent mean pump speeds. The data presented is displayed as the
mean.
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F. Hemodynamic Trade-Offs
While evaluating the hemodynamics achieved using the intelligent LVAD control
strategy, hemodynamic trade-offs were observed between operating settings that gave the
highest degree of LV volume unloading, largest increase in cardiac output, and highest
degree of pulsatility achieved. Our results indicate it may be possible to operate the
intelligent LVAD control strategy to target specifically LV volume unloading, cardiac
output, and/or pulsatility support directly. But with the ability to target each type of
hemodynamic support directly there may also be hemodynamic trade-offs incurred.
1. Left Ventricular Volume Unloading
During this experiment the operating setting that produced the greatest degree of
LV volume unloading by evaluating reductions in LV stroke volume, LV end diastolic
pressure, and LV external work was operating the intelligent LVAD control strategy
asynchronously at a D2500 rpm at a 30% systolic duration while in phases of counterpulsation. This operating setting corresponded to the highest mean pump speed
throughout the experiment and produced the greatest degree of LV volume unloading
while also increasing cardiac output but came with the limitations of decreasing
pulsatility and increasing the power the HVAD used as shown in Table IX.
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TABLE IX
LEFT VENTRICULAR VOLUME UNLOADING HEMODYNAMIC
TRADE-OFFS

∆2500 RPM at 30% Systolic Duration:
during Counter-Pulsation Phases
Cardiac Output
Pulsatility

↑
↓

Power
↑
↑ = Increases; ↓ = Decreases
Table IX. Hemodynamic trade-offs of operating the intelligent LVAD
control strategy to produce the greatest degree of left ventricular (LV)
volume unloading. Cardiac output is also increased while operating the
intelligent LVAD control strategy to produce the greatest LV volume
unloading but diminished pulsatility and increased power usage of the
LVAD.

2. Cardiac Output
Cardiac output had the greatest augmentation in total flow, LVAD flow, and
aortic flow when the intelligent LVAD control strategy was operating asynchronously,
during phases of co-pulsation at a D2500 rpm with a systolic duration of 30%. Operating
at this setting gave the largest increase in cardiac output and greatest degree of LV
volume unloading but came at the limitations of reduced pulsatility and increased HVAD
power usage, as shown in Table X. The aortic flow did not follow this trend (increase in
mean pump speed results in increased total and LVAD flow), as it was generally greater
at lower mean pump speeds. Due to the aortic flow always having a mean forward flow,
the operating setting that gave the highest degree of augmentation in cardiac output
occurred with pump setting of D2500 rpm, systolic duration of 30%, and during phases
of co-pulsation support.
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TABLE X
CARDIAC OUTPUT HEMODYNAMIC TRADE-OFFS

∆2500 RPM at 30% Systolic Duration:
during Co-Pulsation Phases
LV Volume Unloading
Pulsatility

↑*
↓

Power
↑
↑ = Increases; ↓ = Decreases
Table X. Hemodynamic trade-offs of operating the intelligent LVAD
control strategy to produce the greatest increase in cardiac output. Left
ventricular volume unloading also increased while operating the intelligent
LVAD control strategy to produce the greatest increase in cardiac output
but diminished pulsatility and increased power usage of the LVAD. The *
designates that LV volume unloading would be expected to increase in this
operating setting due to operating at a high mean pump speed; but due to
limitations associated with the LV volume catheter the degree to which the
LV is unloaded cannot be specified.

3. Pulsatility
The highest degree of pulsatility was achieved while operating the intelligent
LVAD control strategy asynchronously at a D1000 rpm at 40% systolic duration during
phases of co-pulsation as evidenced by increases in AoP DP, PI, SHE, and vascular
resistance. This operating setting corresponded to the lowest mean pump speed tested
while operating the HVAD in a pulsatile manner using the intelligent LVAD control
strategy. The highest degree of pulsatility had hemodynamic trade-offs, including lower
LV volume unloading and cardiac output with the increased power requirements while
operating the HVAD in a pulsatile manner (Table XI).
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TABLE XI
PULSATILITY HEMODYNAMIC TRADE-OFFS

∆1000 RPM at 40% Systolic Duration:
during Co-pulsation Phases
LV Volume Unloading
↓*
Cardiac Output

↓

Power
↑
↑ = Increases; ↓ = Decreases
Table XI. Hemodynamic trade-offs of operating the intelligent LVAD
control strategy to produce the highest degree of pulsatility. Left ventricular
volume unloading and cardiac output decreased in order to obtain the
highest degree of pulsatility in this study while operating the HVAD using
the intelligent LVAD control strategy. In addition to reducing the degree of
left ventricular volume unloading and augmentation of cardiac output there
was also an increase in power usage of the LVAD. The * designates that
LV volume unloading would be expected to decrease in this operating
setting due to operating at a lower mean pump speed; but due to limitations
associated with the LV volume catheter the degree to which the LV is
unloaded cannot be specified.
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IV. DISCUSSION

A. Key Findings
In this study, we successfully demonstrated that a novel intelligent LVAD control
strategy reliably detected an R-wave from an external EKG and triggered pump speed
(rpm) modulation (rapidly increase and decrease) of a Medtronic HVAD within a single
cardiac cycle. However, unexpectedly the relationship between electrical current and
pump speed (rpm) was non-linear for unknown reasons, which may be associated with
limitations of the intelligent LVAD controller. The results of this study also demonstrated
that mean operating pump speed (rpm) is a function of (1) magnitude of change in pump
speed (Drpm) and (2) time spent at the high and low operating pump speeds (rpm). The
HVAD pump speed modulation settings that produced the greatest ventricular volume
unloading, greatest increase in cardiac output, and greatest pulsatility (DP, SHE) were
identified. Counter-pulsation provided the greatest ventricular volume unloading
compared to co-pulsation at the same mean pump speed (rpm) as characterized by a
greater reduction in LV end diastolic pressure and LV external work. Phases of copulsation support produced the greatest pulsatility and cardiac output compared to phases
of counter-pulsation at the same mean pump speed (rpm) as characterized by a greater
aortic pulse pressure, pulsatility index, surplus hemodynamic energy, total flow, and
LVAD flow. During post-processing and data analysis of the recorded hemodynamic
waveforms for all test conditions, two unexpected time delays were identified: (1) a
computational time delay (ms) between the detection of the R-wave threshold landmark
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and the command to initiate rapid increase in pump speed associated with an algorithm
implementation error, and (2) a hemodynamic time delay between the increase in pump
speed and increase in LVAD flow associated with fluid inertia.

B. Pump Speed Modulation
1.

Thoratec HeartMate 3: Artificial Pulse
The Thoratec HeartMate 3 (Burlington, MA) is a clinically-approved centrifugal

LVAD that is implanted inside the chest with the inflow cannula sutured to the LV and
the outflow cannula routinely grafted to the aorta. The HeartMate 3 provides an artificial
pulse by lowering the operating rpm of the pump by 2000 rpm for 0.15 seconds, followed
by an increase in operating rpm by 4000 rpm for 0.20 seconds, and then lowered to the
original fixed pump speed (Figure 30). The HeartMate 3 pump speed modulation
algorithm operates asynchronously to the native heart to create an artificial pulse that
transitions in and out of phase with the native heart cardiac cycle resulting in flow
reduction (counter-pulsation) phase and flow augmentation (co-pulsation) phases
(Castagna et al., 2017), but cannot be set to function continuously in co-pulsation and
counter-pulsation for a pre-set period of time.

Figure 30. Graphical representation of the Thoratec HeartMate 3 pump speed modulation
technique. Pump speed modulation occurs once every two seconds independent of the cardiac
cycle with a 2000 rpm decrease in pump speed for 0.15 seconds followed by a 4000 rpm increase
in pump speed for 0.20 seconds and then returning to original fixed speed until next pump speed
modulation cycle.
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In a study performed by Krabatsch et al., clinical outcomes data for 50 patients
implanted with the HeartMate 3 were follow-up at one-year post-implant to evaluate
incidence of adverse events, re-hospitalizations, device malfunction, and survival
(Krabatsch et al., 2017). The study concluded lower rates of pump thrombosis (no
incidence), GI bleeds (12%), and no pump failures (mechanical) compared to the reported
adverse events (INTERMACS) of patients supported with other currently available CFLVADs. Although the author reports no incidence of hemolysis and/or pump thrombosis,
the overall rate of stroke was 18% (Krabatsch et al., 2017). The findings in the study
conducted by Krabatsch et al., may support that the pump speed modulation of the
HeartMate 3 may reduce the risks of GI bleeds and pump thrombosis. Additional studies
with durations spanning longer than a year may need to be done in order to see if pump
speed modulation is the main contributing factor to the reduced incidence of adverse
events for the patients implanted with the HeartMate 3.

2.

Lavare Cycle: Medtronic HVAD

The Lavare cycle is a control strategy integrated into the Medtronic HVAD
controller designed to provide intermittent pump washing to help reduce the risk of pump
thrombosis. The Lavare cycle is a pump speed modulation algorithm that rapidly
decreases pump operating speed by 200 rpm for a period of two seconds, followed by a
rapid increase of 400 rpm for one second, and then rapid decrease back to the initial set
pump speed (Figure 31). The Lavare cycle is intended to reduce the occurrence of
thrombus formation by potentially decreasing the areas of blood stasis within the LV by
dynamically varying ventricular volume and pump flow (LaRose et al., 2010).
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Figure 31. Graphical representation of the Medtronic HVAD pump speed modulation technique using the
Lavare cycle. The Lavare cycle operates asynchronously to the native heart with a pump speed modulation
cycle that occurs once per minute. The Lavare cycle decreases pump speed by 200 rpm for two seconds and
then increases the operating rpm by 400 rpm for one second before returning to the original fixed pump
speed.

The hypothesis that the Lavare cycle may decrease the potential for thrombus
formation by reducing blood stasis in the LV is supported by the findings of Zimpfer et
al. They demonstrated that operating a Medtronic HVAD with the Lavare cycle
decreased the stagnation index of the LV by 22% compared to operating at a fixed pump
speed in a MCL model with particle image velocimetry (PIV) analyses (Zimpfer et al.,
2016). They also found that a drop-in pump speed greater than 400 rpm produced
negative flow at the inflow cannula. It is theorized that larger drops in pump speed and/or
longer periods of support at low pump speed settings may promote aortic valve opening
and reduce the risk of GI bleeds by promoting pulsatile flow compared to CF-LVADs
(Zimpfer et al., 2016).

3.

Jarvik 2000: Intermittent Low Speed (ILS)

The Jarvik 2000 (Jarvik Heart, New York, NY) is a clinically-approved axial flow
LVAD that is implanted with the inflow and outflow grafts attached to the LV and
ascending aorta, respectively. The Jarvik 2000 was the first LVAD to use cyclic pump
speed rotation (one cycle per minute) to minimize the risk of thrombus formation by
promoting periodic ejection through the aortic valve, as described in the Jarvik 2000’s
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operating manual (Figure 32). By reducing the operating pump speed of the Jarvik 2000
for a short period of time with the ILS controller, the amount of pump flow and LV
unloading is reduced, and the workload of the heart is increased. During this short period
of time, in which the Jarvik pump operates at lower pump speeds, the heart adapts to the
increase in preload by increasing contractility (Selzman et al., 2018). The native heart is
able to eject a greater volume of blood through the aortic valve, which may result in
better washing of the aortic valve and root, thereby reducing the risk of aortic thrombus.
The Jarvik 2000 ILS controller may also have the added benefit of an increase in
pulsatility at the lowered pump speed setting (Selzman et al., 2018).

Figure 32. Graphical representation of the Jarvik 2000 intermittent low speed (ILS) pump speed
modulation technique. The ILS pump speed modulation technique operates asynchronously to the
native cardiac cycle and reduces operating rpm of the Jarvik 2000 for a short period of time each
minute to allow the native heart to retake the majority of work in pumping blood to the body before
returning to the original fixed pump speed.

Stanfield et al. conducted a study implementing a MCL to compare two bearing
designs for the Jarvik 2000 during support with the ILS algorithm (Stanfield et al., 2013),
and demonstrated average flow was reduced by up to 68% but produced up to 360%
increase in PI for both bearing designs (Stanfield et al., 2013). The finding in this in vitro
study evaluating the intelligent LVAD control strategy supports the theory that a
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reduction in pump speed should result in increased pulsatility that may offer the benefits
of a more physiologic flow pattern and potentially a reduced risk of AI formation, but at
the potential expense of decreasing the degree of LV volume unloading and cardiac
output.
C.

Clinical Impact
The potential clinical impact of this study is the implementation of an intelligent
LVAD control strategy to provide pump speed modulation of CF-LVADs with the ability
to provide pulsatile flow in an asynchronous manner with phases of counter-pulsation and
co-pulsation support. Pump speed modulation is a function of mean pump speed (rpm) as
well as magnitude of rapid changes in pump speed (Drpm) and time period (T, ms) at
high and low pump speed settings. Additionally, effective pump modulation settings may
also be able programmed to provide greatest LV volume unloading, cardiac output,
and/or pulsatility based upon patient-specific needs. If the time delays (or advances) are
implemented into the intelligent LVAD control strategy, pump speed modulation may
target specific phases of the cardiac cycle, such as co-pulsation or counter-pulsation. For
example, if the mean pump speed (rpm) during a pulsatile mode (pump speed
modulation) was kept constant and the magnitude (Drpm) increased around that mean
setting, then counter-pulsation would be expected to have greater hemodynamic benefit
with respect to LV external work and LV end-diastolic pressure compared to the same
co-pulsation mean pump speed (rpm). Also, co-pulsation would be expected to have a
greater hemodynamic benefit for pulsatility and cardiac output when evaluating pulse
pressure, PI, SHE, and total flow if the mean pump speed (rpm) if pulsatile operation of
the intelligent control was kept constant and the Drpm was increased around the same
mean compared to counter-pulsation support. The ability to specify type of pump speed
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modulation support (co-pulsation, counter-pulsation, and asynchronous) specific to a
patient’s need (ex. activity level and time of day) may also be possible to achieve.
A complication that is often present in long-term CF-LVAD support is the
development or progression of aortic insufficiency (AI). AI can develop as a result of the
pressure gradient applied across the aortic valve limiting the opening of the valve due to
the implantation of CF-LVADs. This can result in partial opening or closure of the aortic
valve followed by subsequent distortion of the aortic valves anatomy. (Cowger et al.,
2010). In our mock loop study, we did not identify any regurgitant flow through the
mechanical aortic valve in the MCL model while operating the Medtronic HVAD in a
pulsatile fashion, but regurgitant flow was observed when operating the HVAD at fixed
speeds greater than 3,500 rpm (regurgitant flow up to ~0.75 L/min). This finding supports
the concept that pump speed modulation allows better aortic valve opening by allowing
the heart to produce forward flow through the aortic valve as a result of a lowered
pressure gradient across the aortic valve and may help to reduce the incidence of AI but
needs to be evaluated further utilizing in vivo testing platforms to see the effect on a
biological aortic valve.
Although there are potential benefits to pump speed modulation, a drawback
associated with operating CF-LVADs in a pulsatile manner may be the incidence of
bleeding from the potential of increasing the shear stress that is applied to the blood and
platelets. Bleeding has been hypothesized to occur due to high shear stress on blood
causing acquired von Willebrand syndrome from the continuous rotation of CF-LVAD
impellers (Eckman et al., 2012). Additional studies evaluating the intelligent LVAD
control strategy for blood trauma should be done to evaluate if pump speed modulation of
CF-LVADs increases the risk of bleeding due to the shear stress that can be applied to
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blood and platelets during pump speed modulation. Also, with the high shear stresses
applied on blood hemolysis and platelet damage may occur leading to thrombus
formation may result.

D.

Limitations
By testing the intelligent LVAD control strategy in a MCL model, many
assumptions and associated limitations may impact interpretation of key findings. First,
the MCL model was configured and tuned to mimic key hemodynamic parameters of a
class IV HF patient. Although the MCL model is a valuable tool in the pre-clinical testing
of MCS devices, it cannot reproduce the interactions between a biological system and the
device (HVAD). Second, the MCL is a lumped parameter model and does not have the to
simulate the complex branching network of the circulatory system (multiple vessels,
length, diameter, wall thickness), which may impact vascular pulsatility. Third, the MCL
model does not account for physiologic feedback mechanisms (i.e. Frank Starling,
baroreceptor), thereby limiting evaluation of how intelligent control algorithm
performance and physiologic responses to a dynamic cardiovascular system (ex.
vasoconstriction and vasodilation). Fourth, a blood analog (glycerol-saline) solution
rather than human blood was used, subsequently biological considerations such as blood
trauma, hemolysis, and clotting, were not investigated. Despite these limitations, the
MCL provides a valuable benchtop testing platform to test the feasibility of pump speed
modulation algorithm and hemodynamic performance of the intelligent LVAD control
strategy as an initial step in the pre-clinical development phase required to demonstrate
function, efficacy, reliability, and safety (verification and validation) prior to clinical
implementation.
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A technical limitation of this study was the inability to reliably synchronize the
intelligent control algorithm with the cardiac cycle of the mock ventricle, which limited
operation to asynchronous mode. However, short periods of co-pulsation and counterpulsation phases were achieved when setting mock ventricle (78 bpm) and intelligent
control algorithms (80 cycles/sec), which were instrumental in elucidating the two
unexpected time delays (trigger, inertia effect). The computational delay (trigger) can be
easily corrected in software, and the inertial delay may be corrected by enabling user to
adjust initiation (advance or delay) of pump speed increase (or decrease), similar to an
IABP console. The ability to modulate pump speed comes at the expense of requirement
for increase in power, which may reduce the amount of time the device can be operated
solely on battery power.
An instrumentation limitation of this study was the use of the volume admittance
catheter which did not have the appropriate number of segments and spacings required to
accurately measure the entire volume of the mock ventricle. The volume catheter used in
this study did not allow for the measurement of volume throughout the entirety of the
artificial ventricle, but only at the apex. Additionally, the MatLab calculation of LV
external work from the product of the LV systolic and diastolic pressures (averages) and
forward flow (LV stroke volume) may have resulted in an under estimation of the LV
external work. To address this error, we modified our methods and performed additional
data analysis using LabChart’s software. These limitations may explain why the LV
stroke volume, LV external work, and PV loops did not vary largely with increasing
mean pump speeds as would have been expected.
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Finally, a limitation of the study design was that only single recordings for each
test condition were completed. Subsequently, it did not allow the ability to test for
reproducibility (larger sample size) and statistical analysis between operating settings.

E.

Future Considerations
Next steps for the intelligent LVAD control strategy include additional testing in a
MCL to evaluate the ability to reproduce the data gathered in this experiment and also
increase the sample size to allow for statistical analysis of the data collected.
Additionally, a time delay (or advance) could be implemented to account for the time
delays observed in this study; (1) a computational time delay (ms) between the detection
of the R-wave threshold landmark and the command to initiate rapid increase in pump
speed associated with an algorithm implementation error, and (2) a hemodynamic time
delay between the increase in pump speed and increase in LVAD flow associated with
fluid inertia. This delay (or advance) would facilitate more accurate pump speed ramping
in response to specific points in the cardiac cycle that would allow pump speed
modulation not only in an asynchronous manner but also specifically for co-pulsation and
counter-pulsation support. A time delay (or advance) that allows for specified support
would allow the ability to gather data for co-pulsation, counter-pulsation, and
asynchronous support independently, giving the ability to compare and contrast each type
of support for LV volume unloading, cardiac output, and pulsatility. In future
experiments in which the intelligent LVAD control strategy is able to target support
based on specific points in the cardiac cycle the heart rate at which pump speed
modulation is triggered can be altered. The study design of future experiments can also
be changed to evaluate the intelligent LVAD control strategy at varying heart rates to
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investigate if the intelligent control strategy can modulate pump speed within a cardiac
cycle at higher heart rates. The effect of arrhythmias on the intelligent LVAD control
strategy should be investigated to see how the control algorithm responds to various
arrhythmias such as ventricular tachycardia. Finally, safety measures should be
implemented into the intelligent control algorithm for events such as ventricular wall
suction so the pump speed modulation can be adjusted automatically without having to be
manually manipulated.
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V. CONCLUSION

The results of this study show the ability of the intelligent LVAD control strategy
to increase and decrease pump speed within a single cardiac cycle. This study showed
through asynchronous modulation that phases of co-pulsation can generate near
physiologic pulse pressure and pulsatility when compared to phases of counter-pulsation.
Counter-pulsation phases generated greater ventricular volume unloading when compared
to phases of co-pulsation. Furthermore, the clinical impact of pump speed modulation of
CF-LVADs may result in lower incidence of adverse events associated with CF-LVAD
support such as bleeding and aortic insufficiency but additional testing needs to be
performed in order evaluate the effectiveness of pump speed modulation in living
systems. Additional studies implementing the time delays (or advances) need to be done
in order to show proof of concept in providing co-pulsation and counter-pulsation
support. Also, with the ability to specify pump support the hemodynamic benefits can be
evaluated for each type of support, as well as investigating if it is more beneficial to
modulate pump speed asynchronously to receive the benefits of both co-pulsation and
counter-pulsation support.
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APPENDIX I HEMODYNAMIC WAVEFORMS:
Asynchronous waveforms for a 30% systolic duration:
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Asynchronous waveforms for a 35% systolic duration:
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Asynchronous wavefroms for a 40% systolic duration:
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Counter-pulsation & CO-pulsation waveforms for a 30% systolic duration:
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Counter-pulsation & CO-pulsation waveforms for a 35% systolic duration:
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Counter-pulsation & CO-pulsation waveforms for a 40% systolic duration:
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Fixed Speed Waveforms:
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APPENDIX II HEMODYNAMIC GRAPHS:
Ventricular Volume Unloading Hemodynamic Graphs:
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Pulsatility Hemodynamic Graphs:
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APPENDIX III MATLAB SCRIPT FOR INTELLIGENT CONTROL ANALYSIS:
MatLab Script for Intelligent Control experiment analysis
% This file is adapted from hrt_VAD.m which was originally written by
% Steven Koenig, Ph.D. on November 6, 2001 for the HEART program to
analyze
% Mock Circulatory Loop data from CorWave initial testing.
%
% This file calculates beat-to-beat hemodynamic parameters of mat files
% that were outputted by HEART. AoP or LVP beats must have been picked in
% HEART.
%
% Update 2/28/17 - Calculations for AOP, SHE, EEP have been changed to used
% LVP beat indices (more reliable), and LVP end systolic pressure is now
% calculated based on timing (mock loop timing is more reliable; less noise).
%
% Update 3/37/17 - Added AOP dP/dt and ZART calculations
clear all;
clc;
warning('off','MATLAB:xlswrite:AddSheet');
folderpath = 'S:\CII Unrestricted\Cary Data Dump
Zone\2019_Data\Jake_Thesis\30sys\mat\'; % Set to directory of mat files **NEED
trailing \
d=what(folderpath); % Get everything in directory
filename=d.mat; % Gets all .mat files in the current folder
errors = 0; % initialize to no errors
% List all output labels that you are saving in heartData at the bottom of
% the code. This is to set up an output matrix for later export to Excel
% document. DO NOT REMOVE 'Recording'.
labelList = {'Recording' 'Heart Rate' 'Cardiac Output' 'Ejection Fraction',...
'Mean LAP' 'LAP Systolic' 'LAP Diastolic',...
'Mean LVP' 'LVP Peak Systolic' 'LVP End Systolic' 'LVP End Diastolic'
'LVP +dP/dt' 'LVP -dP/dt',...
'LVV End Systole' 'LVV End Diastole' 'LVV Stroke Volume' 'LV External
Work',...
'Mean AoP' 'AoP Systolic' 'AoP Diastolic' 'DeltaP_AoP' 'Mean AoF',...
'Max AoF' 'Min AoF' 'AoF Systolic Avg' 'AoF Diastolic Avg',...
'Mean AoPd' 'AoPd Systolic' 'AoPd Diastolic',...
'Mean VAD P' ' VAD P Systolic' 'VAD P Diastolic' 'Mean VAD F' 'Max
VAD F' 'Min VAD F' 'VAD F Systolic Avg' 'VAD F Diastolic Avg',...
'Mean TotalFlow' 'TotalFlow peak (+)' 'TotalFlow peak (-)' 'TotalFlowPI'
'ZART' 'SHE' 'EEP' 'ArtPavg' 'ArtPsys' 'ArtPdia' 'DeltaP_ArtP' 'ArtP_PI' 'LVCO'};
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% Set up output matrix for later export to Excel document.
for i=1:length(labelList)
output(i,1) = labelList(i);
end
for i=2:length(labelList)
beatOutput(1,i-1) = labelList(i);
end
numFiles = length(filename);
progress = 0;
h = waitbar(progress,'Initializing data...');
for k=1:length(filename)
% Run for all files in folder
load(strcat(folderpath,filename{k}))
% Load the .mat files one by one
n=filename{k};
% Get filename of current .mat file
outputName = strcat(n(1:end-15),'-analysis');
if k == 1
prevName = outputName;
currentFile = 1;
else
if (strcmp(outputName,prevName) == 0)
output = output.';
xlswrite(prevName, output, 'Sheet1');
output = {};
for i=1:length(labelList)
output(i,1) = labelList(i);
end
prevName = outputName;
currentFile = 1;
else
currentFile = currentFile + 1;
end
end
if isempty(LVPbeatindices) == 1
% return error of no data to analyze
disp(strcat('No LVP beat indices found in .mat file: ',n))
errors = 2;
else % analyze
numbeats = size(LVPbeatindices,1);
% Change HEART variables to real names
AoPd = P1; % AOP Distal
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VADF = VASF; % VAD Flow
VADP = P2; % VAD Pressure
TotalFlow = F1; %Total Flow
AOPRF = AoF % %Root Flow
AOPRM = ArtP % Root Millar
Current = Mrkr
Phase = T
MAG = Gz
AOPRF = AoP
% Initialize data variables
LVHR = zeros(numbeats,1)*NaN;
LVppdPdt = zeros(numbeats,1)*NaN;
LVpndPdt = zeros(numbeats,1)*NaN;
LVPbd = zeros(numbeats,1)*NaN;
LVPavg = zeros(numbeats,1)*NaN;
LVPed = zeros(numbeats,1)*NaN;
LVPpksys = zeros(numbeats,1)*NaN;
LVPes = zeros(numbeats,1)*NaN;
LVEW = zeros(numbeats,1)*NaN;
LVVes = zeros(numbeats,1)*NaN;
LVVed = zeros(numbeats,1)*NaN;
LVVSV = zeros(numbeats,1)*NaN;
LVEF = zeros(numbeats,1)*NaN;
AoPavg = zeros(numbeats,1)*NaN;
AoPsys = zeros(numbeats,1)*NaN;
AoPdia = zeros(numbeats,1)*NaN;
ArtPavg = zeros(numbeats,1)*NaN;
ArtPsys = zeros(numbeats,1)*NaN;
ArtPdia = zeros(numbeats,1)*NaN;
ArtP_PI = zeros(numbeats,1)*NaN;
LAPsys = zeros(numbeats,1)*NaN;
LAPdia = zeros(numbeats,1)*NaN;
LAPavg = zeros(numbeats,1)*NaN;
AoPdsys = zeros(numbeats,1)*NaN;
AoPddia = zeros(numbeats,1)*NaN;
AoPdavg = zeros(numbeats,1)*NaN;
LCAPsys = zeros(numbeats,1)*NaN;
LCAPdia = zeros(numbeats,1)*NaN;
LCAPavg = zeros(numbeats,1)*NaN;
CdAPsys = zeros(numbeats,1)*NaN;
CdAPdia = zeros(numbeats,1)*NaN;
CdAPavg = zeros(numbeats,1)*NaN;
SpinalPsys = zeros(numbeats,1)*NaN;
SpinalPdia = zeros(numbeats,1)*NaN;
SpinalPavg = zeros(numbeats,1)*NaN;
RenalPsys = zeros(numbeats,1)*NaN;
RenalPdia = zeros(numbeats,1)*NaN;
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RenalPavg = zeros(numbeats,1)*NaN;
AoFavg = zeros(numbeats,1)*NaN;
AoFpkpos = zeros(numbeats,1)*NaN;
AoFpkneg = zeros(numbeats,1)*NaN;
AoFsys = zeros(numbeats,1)*NaN;
AoFdia = zeros(numbeats,1)*NaN;
LAFavg = zeros(numbeats,1)*NaN;
LAFpkpos = zeros(numbeats,1)*NaN;
LAFpkneg = zeros(numbeats,1)*NaN;
LAFsys = zeros(numbeats,1)*NaN;
LAFdia = zeros(numbeats,1)*NaN;
CAFavg = zeros(numbeats,1)*NaN;
CAFpkpos = zeros(numbeats,1)*NaN;
CAFpkneg = zeros(numbeats,1)*NaN;
CAFsys = zeros(numbeats,1)*NaN;
CAFdia = zeros(numbeats,1)*NaN;
CdAFavg = zeros(numbeats,1)*NaN;
CdAFpkpos = zeros(numbeats,1)*NaN;
CdAFpkneg = zeros(numbeats,1)*NaN;
CdAFsys = zeros(numbeats,1)*NaN;
CdAFdia = zeros(numbeats,1)*NaN;
SAFavg = zeros(numbeats,1)*NaN;
SAFpkpos = zeros(numbeats,1)*NaN;
SAFpkneg = zeros(numbeats,1)*NaN;
SAFsys = zeros(numbeats,1)*NaN;
SAFdia = zeros(numbeats,1)*NaN;
RAFavg = zeros(numbeats,1)*NaN;
RAFpkpos = zeros(numbeats,1)*NaN;
RAFpkneg = zeros(numbeats,1)*NaN;
RAFsys = zeros(numbeats,1)*NaN;
RAFdia = zeros(numbeats,1)*NaN;
AoFdavg = zeros(numbeats,1)*NaN;
AoFdpkpos = zeros(numbeats,1)*NaN;
AoFdpkneg = zeros(numbeats,1)*NaN;
AoFdsys = zeros(numbeats,1)*NaN;
AoFddia = zeros(numbeats,1)*NaN;
LVCO = zeros(numbeats,1)*NaN;
VADPsys = zeros(numbeats,1)*NaN;
VADPdia = zeros(numbeats,1)*NaN;
VADPavg = zeros(numbeats,1)*NaN;
VADFavg = zeros(numbeats,1)*NaN;
VADFpkpos = zeros(numbeats,1)*NaN;
VADFpkneg = zeros(numbeats,1)*NaN;
VADFsys = zeros(numbeats,1)*NaN;
VADFdia = zeros(numbeats,1)*NaN;
TotalFlowavg = zeros(numbeats,1)*NaN;
TotalFlowpkpos = zeros(numbeats,1)*NaN;
TotalFlowpkneg = zeros(numbeats,1)*NaN;
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TotalFlowpulse = zeros(numbeats,1)*NaN;
TotalFlowsv = zeros(numbeats,1)*NaN;
TotalFlowPI = zeros(numbeats,1)*NaN;
ZARTbt = zeros(numbeats,1)*NaN;
SHE =zeros(numbeats,1)*NaN;
SHEbt = zeros(numbeats,1)*NaN;
EEP =zeros(numbeats,1)*NaN;
EEPbt = zeros(numbeats,1)*NaN;
fs = 400
dt = 1/fs; % Fetch sampling interval and create dt (time interval)
% Filters - requires Signal Processing Toolbox
% See https://www.mathworks.com/help/curvefit/smooth.html
AoPfilt = fastsmooth(AoP,20,2);
AoPfilt = fastsmooth(AoPfilt,20,2);
ArtPfilt = fastsmooth(ArtP,20,2);
ArtPfilt = fastsmooth(ArtPfilt,20,2);
LAPfilt = fastsmooth(LAP,20,2);
LAPfilt = fastsmooth(LAPfilt,20,2);
% Force flow units to be ml/sec
AoF = AoF*1000/60; % Aortic flow
VADF = VADF*1000/60; % VAD flow
TotalFlow = TotalFlow*1000/60

plotcheck = 0;

beats
LVP beat

% Set to 1 to see verification plots and values.

for counter = 1:(numbeats)
if LVPbeatindices(counter,3) == 1

% Do only 'good'

btstart = LVPbeatindices(counter,1);

% Beginning of

btend = LVPbeatindices(counter,2);
btlen = btend-btstart+1;

% End of LVP beat

% Calculate heart rate
LVHR(counter,1) = 60/((btend-btstart)*dt);
percentSystole = .35; % percent systole set on the ventricle driver, will
change between heart conditions
indexEndSys = round(btstart +
((60/LVHR(counter,1))*percentSystole)/dt);
index35 = round(btstart + 0.35*(btend-btstart));
beat length (ref. to pt 1)
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% Index at 35% of

index80 = round(btstart + 0.8*(btend-btstart));
beat length (ref. to pt 1)
index120 = round(btstart + 1.2*(btend-btstart));
beat length (ref. to pt 1)

% Index at 80% of
% Index at 120% of

% Stroke volume routine not needed in SecondHeart study
% Calculate stroke volume in mL
% Use TotalFlow for mock loop testing
if exist('TotalFlow') == 1
% Offset flow
AoFoffset=mean(TotalFlow(index80:btend));
AoFnew = TotalFlow;%-AoFoffset;
% offsets flow
[fmax ifmax] = max(AoFnew(btstart:btend));
% find start pt. of flow
indexback=0;
while AoFnew(btstart+ifmax+indexback-1)>0 &&
(btstart+ifmax+indexback-1)>btstart
indexback = indexback-1;
end
flowb=btstart+ifmax+indexback-1;
% find end pt. of flow
indexfor=0;
while AoFnew(btstart+ifmax+indexfor-1) > 0 &&
(btstart+ifmax+indexfor-1) < btend
indexfor = indexfor+1;
end
flowe=btstart+ifmax+indexfor-1;
% Calculate the SV in mL
% LVSV(counter,1) = trapz(AoFnew(flowb:flowe))*dt; % IGNORES
NEGATIVE FLOW
LVSV(counter,1) = trapz(AoFnew(btstart:btend))*dt;
end
% Calculate left ventricular parameters (+dP/dt,-dP/dt,Pbd,Ped,Ppksys)
if exist('LVP') == 1
% Calculate the slope of LVP at each data point for beat 'counter'
LVslopes=[];
LVslopes(1:(btlen),1) = [1/(12*dt)]*[LVP(btstart-2:btend-2,1)8*LVP(btstart-1:btend-1,1)+8*LVP(btstart+1:btend+1,1)-LVP(btstart+2:btend+2,1)];
pressure as an

% Calculate peak positive (dP/dt) and peak negative (-dP/dt) LVP

% index of contractility using previous 'slope' routine
[LVppdPdt(counter,1),LVmaxsi] = max(LVslopes); % LVmaxsi =
max slope index (within bt. index)
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[LVpndPdt(counter,1),LVminsi] = min(LVslopes); % LVminsi = min
slope index (within bt. index)
% Calculate LV diastolic beginning (LVPbd) and ending
(LVPed)pressures and LV systolic pressure
postol = 100; % set high threshold for LVPed
negtol = 0;
% set low threshold for LVPbd
maxLVPbd=30;
% set max. LVPbd pressure threshold
LVPbtstep = LVminsi; %create pt by pt increment counter 'step' to
find LVPbd pt
while LVslopes(LVPbtstep,1) < negtol % find LVPbd pt
LVPbtstep = LVPbtstep + 1;
if LVPbtstep >= btlen, break, end; % error check - if can't find
LVPbd at slope = 0
end
LVPbd(counter,1) = LVP(btstart+LVPbtstep-1);
%
Calculate Pbd = LVP beginning diastole
LVPavg(counter,1) = mean(LVP(btstart:btend));
LVPed(counter,1) = LVP(btend);
% Calculate Ped = LVP end
diastole at end of beat
[LVPpksys(counter,1),indexMaxLVP] = max(LVP(btstart:btend-1));
% Calculate LVPsys = LV systolic pressure (max LVP)
%[LVPpksys(counter,1),indexES] = max(LVP(btstart:btend-1));
[LVPes(counter,1),indexEnS] = max(LVP(indexEndSys15:indexEndSys+15));
indexED = btend;
indexES = indexEndSys - 15 + indexEnS;
end

btlen,

% Calculate LV external work 'LVEW'(ref Sunagawa, 1983)
% Use TotalFlow for mock loop testing
if exist('LVP') == 1 && exist('AoF') ==1
negtol = 0;
bstep = LVminsi;
while LVslopes(bstep,1) < negtol; bstep = bstep + 1; if bstep >=
break, end; end

[fmax ifmax] = max(AoF(btstart:btend));
% find start pt. of flow
indexback=0;
while AoF(btstart+ifmax+indexback-1)>0 &&
(btstart+ifmax+indexback-1)>btstart
indexback = indexback-1;
end
flowb=btstart+ifmax+indexback-1;
% find end pt. of flow
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indexfor=0;
while AoF(btstart+ifmax+indexfor-1) > 0 &&
(btstart+ifmax+indexfor-1) < btend
indexfor = indexfor+1;
end
flowe=btstart+ifmax+indexfor-1;
LVPdavg = mean(LVP(btstart+bstep-1:btend)); % LVP avg.
diastolic pressure. Temp. variable.
LVPsavg = mean(LVP(flowb:flowe));
% LVP avg. systolic
pressure. Temp. variable.
LVEW(counter,1) = sum((LVP(flowb:flowe)LVPdavg).*AoF(flowb:flowe)).*dt; % New EW method.
end
% Calculate LV end-systolic, end-diastolic, and stroke volumes
if exist('LVV') == 1
LVVed(counter,1) = max(LVV(btstart:btend));
LVVes(counter,1) = min(LVV(btstart:btend));
LVVSV(counter,1) = LVVed(counter,1)-LVVes(counter,1);
LVEF(counter,1) = LVVSV(counter,1) / LVVed(counter,1) * 100;
end
% This routine is used to calculate aortic root peak systolic, min
diastolic, and mean pressures
if exist('AoP') == 1
if LVPbeatindices(counter,3) == 1
btstartAo = LVPbeatindices(counter,1);
btendAo = LVPbeatindices(counter,2);
btlenAo = btendAo-btstartAo+1;
AoP(indexES+5:indexED) = AoPfilt(indexES+5:indexED);
AoPavg(counter,1) = mean(AoP(btstartAo:btendAo));
% Grab AoPsys point using the LVPsys index
AoPsys(counter,1) = AoP(indexES);
AoPdia(counter,1) = AoP(indexED);
DeltaP_AoP = AoPsys - AoPdia;
end
end
if exist('ArtP') == 1
if LVPbeatindices(counter,3) == 1
btstartArt = LVPbeatindices(counter,1);
btendArt = LVPbeatindices(counter,2);
btlenArt = btendArt-btstartArt+1;
ArtP(indexES+5:indexED) = ArtPfilt(indexES+5:indexED);
ArtPavg(counter,1) = mean(ArtP(btstartArt:btendArt));
% Grab AoPsys point using the LVPsys index
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ArtPsys(counter,1) = ArtP(indexES);
ArtPdia(counter,1) = ArtP(indexED);
DeltaP_ArtP = ArtPsys - ArtPdia;
ArtP_PI = DeltaP_ArtP/ArtPavg
end
end
progress = progress + ((1 / numFiles) * .325 * (1 / numbeats));
progressText = num2str(progress*100,'%.2f');
waitText = strcat(progressText,'% complete...
(',num2str(k),'/',num2str(numFiles),' files analyzed)');
waitbar(progress,h,waitText)
mean pressures

% This routine is used to calculate LA max systolic, min diastolic, and
if exist('LAP') == 1
%LAP(indexES+5:indexED) = LAPfilt(indexES+5:indexED);
LAPsys(counter,1) = LAP(indexES);
LAPdia(counter,1) = LAP(indexED);
LAPavg(counter,1) = mean(LAP(btstart:btend-1));
end
if exist('AoPd') == 1
AoPdsys(counter,1) = AoPd(indexES);
AoPddia(counter,1) = AoPd(indexED);
AoPdavg(counter,1) = mean(AoPd(btstart:btend-1));
end
if exist('VADP') == 1
VADPsys(counter,1) = VADP(indexES);
VADPdia(counter,1) = VADP(indexED);
VADPavg(counter,1) = mean(VADP(btstart:btend-1));
end

if exist('AoF') ==1
AoFavg(counter,1) = mean(AoF(btstart:btend))*60/1000;
calculate mean flow
AoFpkpos(counter,1) = max(AoF(btstart:btend))*60/1000;
calculate peak positive flow
AoFpkneg(counter,1) = min(AoF(btstart:btend))*60/1000;
calculate peak positive flow
AoFsys(counter,1) = mean(AoF(btstart:indexES));
calculate average systolic flow
AoFdia(counter,1) = mean(AoF(indexES:btend));
calculate average diastolic flow
end
if exist('VADF') ==1
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%
%
%
%
%

VADFavg(counter,1) = mean(VADF(btstart:btend))*60/1000;
% calculate mean flow
VADFpkpos(counter,1) = max(VADF(btstart:btend))*60/1000;
% calculate peak positive flow
VADFpkneg(counter,1) = min(VADF(btstart:btend))*60/1000;
% calculate peak positive flow
VADFsys(counter,1) = mean(VADF(btstart:indexES));
calculate average systolic flow
VADFdia(counter,1) = mean(VADF(indexES:btend));
% calculate average diastolic flow
end

%

if exist('TotalFlow') ==1
TotalFlowavg(counter,1) = mean(TotalFlow(btstart:btend))*60/1000;
% calculate mean flow
TotalFlowpkpos(counter,1) =
max(TotalFlow(btstart:btend))*60/1000;
% calculate peak positive flow
TotalFlowpkneg(counter,1) =
min(TotalFlow(btstart:btend))*60/1000;
% calculate peak positive flow
TotalFlowsys(counter,1) = mean(TotalFlow(btstart:indexES));
% calculate average systolic flow
TotalFlowdia(counter,1) = mean(TotalFlow(indexES:btend));
% calculate average diastolic flow
TotalFlowPI = ((TotalFlowpkpos - TotalFlowpkneg)/TotalFlowavg);
end
% Calculate SHE and EEP and ZART beat-to-beat
if exist('ArtP') == 1 && exist('TotalFlow') ==1
if LVPbeatindices(counter,3) == 1
btstartArtP = LVPbeatindices(counter,1);
btendArtP = LVPbeatindices(counter,2);
ArtPmbt(counter,1) = mean(ArtP(btstartArtP:btendArtP));
EEPbt(counter,1) =
(trapz(ArtP(btstartArtP:btendArtP).*TotalFlow(btstartArtP:btendArtP))*dt)/(trapz(TotalF
low(btstartArtP:btendArtP))*dt); %in mmHg
if EEPbt(counter,1) < 0
EEPbt(counter,1) = NaN;
end
SHEbt(counter,1)=1332*(EEPbt(counter,1)-ArtPmbt(counter,1));
%units = ergs/cm^3
if SHEbt(counter,1) < 0
SHEbt(counter,1) = NaN;
end
EEP (counter,1) =
(trapz(AoP.*TotalFlow)*dt)/(trapz(TotalFlow)*dt);
MAP (counter,1)= mean(AoP);
SHE (counter,1)= 1332*(EEP(counter,1)-MAP(counter,1));
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% BEGIN ZART beat-to-beat
ArtPdynes=ArtP*1333;
%converting to dynes/cm^2
thresh = 0.02; % set fractional threshold on flow fft magnitude
fftstart=btstartArtP;
fftend=btendArtP;
epochl = fftend-fftstart+1;
% length of epoch being
analyzed
fft
dyne-sec/cm5

xxx=fft(ArtPdynes(fftstart:fftend-1))/(epochl-1);

% pressure

yyy=fft(TotalFlow(fftstart:fftend-1))/(epochl-1); % flow fft
ZZZ=xxx./yyy;
% input impedance in

ZARTbt(counter,1) = ZZZ(1);
impendence at 0Hz (first harmonic; DC term)
end
end

% ZART is the input

%Plotting routine to verify correction waveform analysis
if plotcheck==1; figure
%Check LVP
plotys(LVP(btstart:btend)); hold on
hline = refline([0 LVPavg(counter,1)]); hline.Color = 'r';
plot(find(LVP(btstart:btend)==LVPpksys(counter,1),1,'last'),LVPpksys(counter,1),'ro');
plot(find(LVP(btstart:btend)==LVPed(counter,1),1,'last'),LVPed(counter,1),'ro'); pause
close
% Check Ao
plotys(AoP(btstart:btend)); hold on
hline = refline([0 AoPavg(counter,1)]); hline.Color = 'r';
plot(find(AoP(btstart:btend)==AoPsys(counter,1),1,'last'),AoPsys(counter,1),'ro');
plot(find(AoP(btstart:btend)==AoPdia(counter,1),1,'last'),AoPdia(counter,1),'ro'); pause
close
% Check AoPd
plotys(AoPd(btstart:btend)); hold on
hline = refline([0 AoPdavg(counter,1)]); hline.Color = 'r';
plot(find(AoPd(btstart:btend)==AoPdsys(counter,1),1,'last'),AoPdsys(counter,1),'ro');
plot(find(AoPd(btstart:btend)==AoPddia(counter,1),1,'last'),AoPddia(counter,1),'ro');
pause
close
end
end % End of good beat if-statement
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end % End of beat by beat 'counter' loop
progress = progress + (1 / numFiles * .325);
progressText = num2str(progress*100,'%.2f');
waitText = strcat(progressText,'% complete...
(',num2str(k),'/',num2str(numFiles),' files analyzed)');
waitbar(progress,h,waitText)
% Calculate cardiac output = sv x hr as a single matrix
% multiplication. Use TotalFlow for mock loop with VAD study.
if exist ('LVV') == 1
LVCO = LVVSV.*LVHR/1000; % Use for flows recorded in L/min (that
were calculated into mL/sec)
%
LVCO = LVSV.*LVHR; % Use for flows recorded in mL/min (that
were converted to mL/sec)
end
heartData = [LVHR LVCO LVEF LAPavg LAPsys LAPdia, ...
LVPavg LVPpksys LVPes LVPed LVppdPdt LVpndPdt LVVes
LVVed LVVSV LVEW, ...
AoPavg AoPsys AoPdia DeltaP_AoP AoFavg AoFpkpos AoFpkneg
AoFsys AoFdia,...
AoPdavg AoPdsys AoPddia,...
VADPavg VADPsys VADPdia VADFavg VADFpkpos
VADFpkneg VADFsys VADFdia,...
TotalFlowavg TotalFlowpkpos TotalFlowpkneg TotalFlowPI EEPbt
SHEbt ZARTbt,...
ArtPavg ArtPsys ArtPdia DeltaP_ArtP ArtP_PI LVCO];

for i=2:numbeats+1
for j=1:length(labelList)-1
beatOutput{i,j} = heartData(i-1,j);
end
end
xlswrite(outputName, beatOutput, n(1:end-4));
beatOutput = {};
for i=2:length(labelList)
beatOutput(1,i-1) = labelList(i);
end
stats = [];
[row,col] = size(heartData);
for column = 1:col
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data = heartData(:,column);
stats(column,1) = nanmean(data(isfinite(data)));
stats(column,2) = std(data(isfinite(data)));
end
errors = 0;
end % End of 'isempty' if statement for analysis block (LVP beat check)
output{1,currentFile*2} = strcat(n(1:end-4),' Means');
output{1,currentFile*2+1} = strcat(n(1:end-4),' Std Devs');
for i=2:length(labelList)
output{i,currentFile*2} = stats(i-1,1);
output{i,currentFile*2+1} = stats(i-1,2);
end
if (k == length(filename))
output = output.';
xlswrite(prevName, output, 'Sheet1');
end
waitText = strcat(progressText,'% complete...
(',num2str(k),'/',num2str(numFiles),' files analyzed)');
waitbar(progress,h,waitText)
progress = progress + (1 / numFiles * .35);
progressText = num2str(progress*100,'%.2f');
end % End of main for loop
close(h)
warning('on','MATLAB:xlswrite:AddSheet');
clear all
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APPENDIX IV MASTER MATLAB DATA SPREADSHEETS:
Fixed Speed:
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30% systolic duration counter-pulsation:
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30% systolic duration counter-pulsation:
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30% systolic duration co-pulsation:
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30% systolic duration co-pulsation:
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35% systolic duration counter-pulsation:
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35% systolic duration counter-pulsation:
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35% systolic duration co-pulsation:
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35% systolic duration co-pulsation:
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40% systolic duration counter-pulsation:
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40% systolic duration counter-pulsation:
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40% systolic duration co-pulsation:
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40% systolic duration co-pulsation:
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